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Breast cancer risk alleles in separate gene regulatory
elements across 6q25 regulate the ESR1, RMND1
and CCDC170 genes and alter breast tumour traits
Alison Dunning, Edwards S., Michailidou K., Kuchenbaecker K,
Thompson D., Lopez-Knowles E., Dowsett M.,
Pharoah P., Garcia-Closas M., Chene
Centre for Cancer Genetic Epidemiology, Cambridge University
Genetic variants at 6q25 are associated with breast cancer in the
general population and in BRCA1 mutation carriers. To identify the
causal variants underlying these associations, we analysed 3872 SNPs
across 6q25 in 118,816 subjects from three international consortia.
We observed five separate regions of association—surrounding
ESR1—the most obvious target gene in the region. We used epi-
demiological methods to define the best causal candidate variants and
examined their phenotypic associations:
At four of the five regions, the causal candidate risk alleles display
a stronger association with oestrogen receptor-negative (ER-) than
oestrogen receptor-positive (ER+) tumours. Three of these four are
associated with ‘‘triple-negative’’ and the fourth with HER2+ tumour
subtypes. Two are additionally associated with mammographic den-
sity. The candidate causal variants in the fifth region are more
strongly associated with high-grade ER+ breast tumours.
These causal candidates lie in five cis-regulatory elements. Chromo-
some conformation capture confirmed that these elements directly contact
the promoters of theESR1,RMND1,ARMT1andCCDC170genes. In the
ER-associated regions, the best causal candidates overlap four separate
enhancers and reporter assays indicated their risk alleles putatively reduced
expression of ESR1, RMND1 and CCDC170. These findings were vali-
dated using immunohistochemical and other studies. Luciferase assay
constructs carrying the causal candidate risk alleles decreased ESR1,
RMND1 and CCDC170 promoter activity. By contrast, the risk alleles
most strongly associated with ER+ tumour risk disrupt a silencer element
and increase ESR1 and RMND1 expression.
Risk alleles disrupting the enhancer elements reduce oestrogen
receptor expression and increase the risk of ER- tumour subtypes, while
disrupting the silencer element increases oestrogen receptor expression
and risk of high-grade ER+ tumours, suggesting there may be a
‘‘Goldilocks level’’ of ESR1 expression for breast cancer protection.
Disrupting coordinated cytoskeletal networks
inactivates cancer-associated fibroblasts and deters
breast cancer progression
Fernando Calvo, Romana Ranftl, Steven Hooper, and Erik Sahai
The Institute of Cancer Research, London
Cancer-associated fibroblasts (CAFs) are non-malignant cells
prominently found in human breast cancers. CAFs can favour tumour
progression, dissemination and therapeutic resistance through
remodelling of the extracellular matrix and signalling to cancer,
endothelial and immune cells. Targeting CAFs represents an alter-
native for therapeutic intervention. Our goal is to identify crucial
mechanisms governing the tumour-promoting phenotype of CAFs
that, once targeted, inactivate CAFs and deter tumour progression.
We isolated fibroblasts from different stages of breast cancer
progression and normal counterparts, and analysed their phenotype,
function and gene expression. Our analyses revealed that enhanced
mechano-transduction and activation of the transcriptional regulator
YAP are signature features of CAFs. YAP regulates the expression of
cytoskeletal genes that are required for the maintenance of the CAF
phenotype and for their ability to remodel the extracellular matrix and
promote cancer cell invasion and angiogenesis. Matrix stiffening
further enhances YAP activation, thus establishing a feed-forward
self-reinforcing loop that helps to maintain the CAF phenotype. In
addition, we identified Cdc42EP3, a previously uncharacterised
Cdc42 effector, as a key regulator of CAFs. Cdc42EP3 links actin and
septin fibres and is upregulated early in fibroblast activation.
Cdc42EP3 induces a profound cytoskeletal rearrangement in CAFs
that enables mechano-transduction and the emergence of pro-tu-
morigenic functions, which are also dependent on the presence of a
septin fibrillary network.
Our studies show how mechanical inputs in solid tumours mod-
ulate the aggressive behaviour of stromal fibroblasts. We demonstrate
a critical role for coordination between the actin and the septin net-
works in CAFs that is required for mechano-transduction, force-
mediating matrix remodelling and promoting cancer cell invasion,
angiogenesis and tumour growth. Finally, we describe the mechanism
of action of Cdc42EP3 and define a novel molecular and biological
role for septins in CAFs.
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Patient-derived xenograft models of breast cancer
with human immune components
Rebecca Marlow1, Kristina Ilieva1,2, Fernanda Kyle3, Erika
Francesch1, Panagiotis Karagiannis2, Patrycja Gazinska, Frank
Nestle, Adrian Hayday3, Sophia Karagiannis1,2, Andrew Tutt1
1Breast Cancer Now Research Unit, Division of Cancer Studies,
Faculty of Life Sciences and Medicine, King’s College London SE1
9RT, UK; 2Skin Science, Division of Genetics and Molecular
Medicine, Faculty of Life Sciences and Medicine, King’s College
London SE1 9RT, UK; 3Peter Gorer Department of Immunobiology,
Division of Immunology, Infection & Inflammatory Disease, Faculty
of Life Sciences and Medicine, King’s College London SE1 9RT, UK
Background It is now recognised that many cancers, including breast,
elicit immune cell engagement resulting in response directed against
overexpressed or aberrantly presented antigens. A greater understanding
of these interactions has significantly improved prognosis in other tumor
types. Here we aim to build disease-relevant in vivo models of breast
cancer that recapitulate the immune tumour microenvironment. Patient-
derived xenografts (PDX) are in vivo preclinical models derived from
transplantation of patient tumour into immunocompromised hosts. These
models recapitulate major clinicopathologic features of patient tumours.
However, as they are maintained in immunocompromised hosts, we
cannot study interactions between tumour and immune cells. In order to
address this, we established humanised breast cancer PDX models.
Method We developed humanised TNBC PDX models in NSG mice,
based on those used in melanoma. The PDX tumour is established by
orthotopic transplantation. Host is then engrafted with human immune
effector cells (peripheral blood lymphocytes (PBL) from healthy
volunteers or matched patient). Following tumour development, tis-
sues are processed for analysis.
Results We observe *40 % engraftment of human immune effector
cells in host spleens following tumor development by flow analysis.
We also observe human CD45 + leukocyte populations in the tumour,
blood and other organs. Tumour-infiltrated lymphocytes (TIL)
expressed the immune checkpoint phenotype of patient cancers. We
are now investigating the subtypes of TIL present in our model,
whether novel antibody-based therapies can be used to block tumour
formation, and how immune checkpoints are modulated.
Conclusion Our overarching aim is to determine whether these models
recapitulate immune responses directed against tumor antigens in order
to study mechanisms of action and efficacy of novel therapeutics to
treat breast cancer. Preclinical humanised PDX models may be feasible
approaches to accelerate therapeutic discovery relevant to impacting
tumour and immune stromal interaction for patient benefit.
Long-term neoadjuvant endocrine treatment
as a clinical model of breast cancer dormancy
Cigdem Selli, Arran K. Turnbull, Renshaw L.,
Thomas J.S., J. Michael Dixon, Andrew H. Sims
Applied Bioinformatics of Cancer, Edinburgh Cancer Research
Centre, Institute of Genetics and Molecular Medicine, The University
of Edinburgh
Aim A minority of oestrogen receptor (ER)-positive breast tumours
treated with neoadjuvant aromatase inhibitors maintain a stable size by
becoming dormant and continue to receive extended treatment and
therefore represent the best currently available clinical model to
investigate dormancy. We aimed to determine genome-wide expression
profiles of dormant cancer cells from breast tumour biopsies that have
received extended neoadjuvant letrozole.
Patients and methods All patients were classified as ‘‘responders’’
based upon ultrasound measurements after 3 months of letrozole
treatment and did not have a recurrence by the latest biopsy.
Expression analysis was performed using Illumina BeadChips. R and
BioConductor packages were used for analysis. Differentially
expressed genes were determined using paired Rank Products (FDR,
5 %). Pathway analysis was performed using Panther database.
Findings A total of 13 patient-matched ‘dormant’ ([6 months
treatment) and baseline samples were compared with each other and
earlier on-treatment biopsy samples. A total of 358 genes were sig-
nificantly differentially regulated (90 down, 268 up) between paired
baseline and long-term treatment samples from patients with ‘dor-
mant’ tumours. A subset of genes (79 down, 255 up) were found to be
uniquely altered during long-term letrozole treatment, and functional
analysis revealed that they were enriched for a number of cancer-
related pathways, including angiogenesis, cadherin signalling, cell
cycle and blood vessel development. Changes in gene expression in
patients that have recurrences under long-term letrozole treatment
will be determined and further compared with dormancy signature.
Conclusion This is the first patient-matched gene expression study to
look at aromatase inhibitor-induced dormancy in breast cancer. Our
results may help to characterise extended growth suppression in
letrozole-treated dormant-state breast cancer cells.
Synthetic lethality and viability: how does BRCA1
interact with 53BP1?
Jo Morris
Institute of Cancer and Genomic Sciences, University of Birmingham
Whether or not the intrinsic activity of the breast and ovarian cancer
predisposition protein BRCA1 as an E3 ubiquitin ligase plays any part
in suppressing genomic instability has been controversial. Through
mutation of a novel element within the dimeric RING domains of the
BRCA1:BARD1 complex, we demonstrate the ligase activity is
required for a subset of BRCA1 functions in the damage response.
Significantly, we show that the ubiquitin ligase activity is a key deter-
minant of how BRCA1 counters the inhibitory influence of 53BP1 on
DNA resection to promote homologous recombinational DNA repair.
Evidence indicating how this is achieved will be presented. The highest
density of patient missense changes are found within the region of
BRCA1 that directs ligase activity, and our findings indicate mutational
status will be significant in therapy choice and resistance mechanisms
associated with synthetic viability. More widely, these findings func-
tionally illustrate the multifaceted role of BRCA1 in the DNA damage
response, suggesting new approaches to overcome resistance mediated
by loss of 53BP1 or 53BP1 effector pathways.
Functional characterisation of low-frequency mutations
in breast cancer
Andri Leonidou, Sarah L. Maguire, Patty T. Wai, Paul Huang,
Barrie Peck and Rachael C. Natrajan
The Institute of Cancer Research, London
Next-generation sequencing efforts have unveiled a vast complexity
in the mutational repertoire of breast cancer. Aside highly recurrent
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mutations in known driver genes such as TP53 and PIK3CA, the vast
majority of mutations occur at low frequencies in unselected breast
cancers and remain uncharacterised.
Our aims were to functionally investigate the significance of
potentially oncogenic mutations in breast cancer in order to identify
novel drivers and therapeutic targets. To this end, we compiled a
database of mutations identified from publicly available and in-house
breast cancer sequencing data. High-confidence variants were run
through bioinformatic prediction algorithms FATHMM and CHASM
to assess their oncogenic impact, and CANSAR was used to annotate
the genes which are druggable. Following several exclusion criteria
and manual curation, the list was limited to 22 missense mutations
across 8 tyrosine kinases.
Mutant and wild-type cDNA constructs were transduced into a
panel of cell lines in order to characterise the phenotypic impact of
mutations using in vitro 2D and 3D assays.
We found FGFR2 hotspot mutations to be constitutively active,
showing a high global phosphorylation state consistent with previous
reports. Cells carrying this mutation were sensitive to siRNA-mediated
silencing of FGFR2 and chemical inhibition with AZD4547 and
PD173074. INSRRdemonstrated a context-dependent phenotype, and its
expression has been correlated with outcome. Kinase domain mutations
conferred a proliferative advantage when cells were grown in 2D culture.
Thiswasmore pronounced in 3D spheroids, suggesting that features such
as cell–cell contact, oxygen and pH gradients across the spheroids better
recapitulate physiological conditions and present a more appropriate
system for the assessment of moderate-impact drivers.
Overall, we found that some lower frequency kinase mutations are
oncogenic. However, the impact of some of these can only be fully
understood in conditions that more closely resemble in vivo condi-
tions, such as 3D culture.
Modelling the tumour microenvironment and
employing functional genomics identifies CREBBP as a
novel tumour surpressor in triple negative breast
cancers
Barrie Peck, Sarah Maguire, Eamonn Morrison, Patty Wai,
Rachael Natrajan
The Institute of Cancer Research, London
Recent next-generation sequencing studies have comprehensively
mapped the genetic landscape of breast cancer and revealed that only
a small number of genes are recurrently mutated in more than 10 % of
unselected tumours (i.e. TP53, PIK3CA and GATA3), and that the
vast majority of recurrent mutations occur at low frequencies.
Although some have been shown to be drivers, i.e. confer a selective
advantage, there are a myriad of significantly altered lower frequency
mutations whose functional impact is unknown. We utilized a func-
tional genomics approach silencing the 200 most frequently mutated
genes in breast cancer in 3-dimensional (3D) spheroid cultures, using
the MCF10a progression series cell line panel to identify novel loss-
of-function mutations that affect breast cancer progression from non-
malignant to highly invasive disease.
Using cancer cell spheroids to more accurately recapitulate in vivo-
like conditions, we identified 11 genes whose silencing with siRNA
impacted growth in two or more cell lines in 3D. Furthermore, a second
targeted validation screen showed that silencing of a cohort of these
genes had limited effect under traditional 2D culture conditions. The
silencing of the histone acetyltransferase CREBBP promoted growth in
AT1, DCIS.com and CA1H cells in 3D while having no effect in 2D
cultures. Investigation of The Cancer Genome Atlas (TCGA) showed
that CREBBP was more frequently mutated in triple-negative breast
cancers (TNBCs). Moreover, at least a third of TNBCs also displayed
haploinsufficient loss of CREBBP and this loss resulted in the upreg-
ulation of the pro-proliferative transcription factor FOXM1.
Multivariate analysis of CREBBP expression showed that CREBBP
loss was significantly associated with decreased relapse-free survival.
In summary, using a functional genomics approach in 3D models
we found that CREBBP silencing promotes growth in tumour
spheroids. Furthermore, CREBBP activity is altered in a significant
proportion of TNBCs and associated with decreased relapse survival.
Synthetic lethal approaches to target ARID1A deficient
breast cancer
Saira Khalique, C.T. Williamson, H Pemberton,
P. T. Wai, M. Menon, R. Brough, A. Leonidou,
B. Peck, R. C. Natrajan and C. J. Lord
The Institute of Cancer Research, London
Dysregulation of the SWI/SNF complex is one of the most commonly
occurring defects in solid cancers; in many cases, SWI/SNF defects are
caused by loss-of-function mutations in the tumour suppressor
ARID1A (AT-rich interactive domain-containing protein 1A). Muta-
tions in ARID1A occur in around 4 % of unselected breast cancers, the
vast majority being loss-of-function frameshift or nonsense mutations,
resulting in loss of protein function. In addition, loss of ARID1A
expression is a common occurrence in breast tumours, especially in
high-grade tumours, and is correlated with a poor prognosis.
Despite the understanding that ARID1A defects are associated
with tumourigenesis, targeted therapy approaches that exploit this
deficiency have not as yet been developed. To this end, we have
devised a large-scale functional genomics approach to identify
actionable ARID1A synthetic lethal effects. Using a high-throughput
drug screen with a plate library of 80 compounds that are currently
licenced or in early phase trials, in isogenic ARID1A null and wild-
type MCF10A cells, we have identified a series of novel ARID1A
synthetic lethal effects. Subsequent drug combination studies have
identified candidate therapeutic approaches to targeting ARID1A
mutant tumours that could be assessed in proof-of-concept clinical
trials. Assessment of this combinatorial approach in in vivo models of
ARID1A mutant cancers is now underway. In conclusion, we have
identified clinically actionable combinatorial approaches that may
provide additional therapeutic benefit for ARID1A deficient patients.
PIM1 kinase regulates cell death, tumour growth
and chemotherapy resistance revealing a novel target
in triple-negative breast cancer
Fara Brasó-Maristany1,2, Simone Filosto1,2, Steven Catchpole1,2,
Rebecca Marlow1,2, Jelmar Quist1,2, Erika Francesch
Domenech1,2, Darren A. Plumb1,2, Leila Zakka1,2, Patrycja
Gazinska1,2, Gianmaria Liccardi3, Pascal Meier3, Albert Gris-
Oliver4, Maggie Chon U. Cheang3, Anna Perdrix Rosell1,2, Manar
Shafat1,2, Elodie Noël1,2, Nirmesh Patel1,2, Kristen McEachern5,
Maurizio Scaltriti6,7, Pau Castel6,7, Farzana Noor1,2, Richard
Buus3, Sumi Mathew1,2, Johnathan Watkins1,2, Violeta Serra4,
Pierfrancesco Marra1,2, Anita Grigoriadis1,2, Andrew N. Tutt1,2,3
1Breast Cancer Now Research Unit, King’s College London, UK;
2Department of Research Oncology, King’s Health Partners AHSC,
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Faculty of Life Sciences and Medicine, King’s College London, UK;
3The Breast Cancer Now Toby Research Centre, The Institute
of Cancer Research, London, UK; 4Experimental Therapeutics Group,
Vall d’Hebron Institute of Oncology, Barcelona, Spain; 5Oncology
iMed, AstraZeneca, Waltham, Massachusetts, USA; 6Department
of Medicine, Memorial Sloan Kettering Cancer Center, New York,
USA; 7Department of Pathology, Memorial Sloan Kettering Cancer
Center, New York, USA
Background Triple-negative breast cancers (TNBCs) have poor
prognosis and lack targeted therapies, mainly due to the absence of
suitable molecular targets. The genomic region 6p21–p25 is recur-
rently amplified in TNBCs and encompasses the PIM1 oncogene.
PIM1 belongs to the PIM kinase family, implicated in the control of
cancer cell proliferation, apoptosis and migration, particularly in
leukaemia and prostate cancer. The activity of PIM1 in these cancers
has been closely linked to the regulation of c-MYC, an untar-
getable oncogene frequently amplified and overexpressed in primary
and in chemotherapy-resistant TNBCs.
Methods Genomic breast cancer datasets were interrogated to
establish PIM1 copy number and transcript levels. To elucidate the
role of PIM1 in malignant phenotypes of TNBCs, RNA interference
and rescue-of-function experiments were carried out in breast cancer
and non-malignant mammary epithelial cell line models. The ther-
apeutic potential of targeting PIM1 in vitro and in vivo was assessed
using AZD1208, a small-molecule inhibitor of the PIM kinase
family.
Results Interrogation of genomic datasets identified increased PIM1
copy number-driven expression in TNBC. Functional studies revealed
addiction to PIM1 kinase for cell population growth and apoptosis pro-
tection in TNBC cells, absent in non-malignant cells. PIM1 knockdown
reduced BCL2 expression, and dynamic BH3 profiling analysis revealed
that PIM1 prevents mitochondrial-mediated apoptosis in TNBC cell
lines.PIM1 expression was associated with several MYC transcriptional
signatures and promoted cell population growth through regulation of
c-MYC and transcription of MYC targets, including MCL1. We further
demonstrated PIM1 regulation of established TNBC oncogenic proteins
SHP2 and EPHA2 and cell cycle inhibitor p27. AZD1208 inhibited
growth and sensitised TNBC cell lines, xenografts and patient-derived
xenografts to standard-of-care chemotherapy.
Conclusion Targeting PIM1 is a very promising therapeutic strategy
for TNBC, a particularly challenging and often chemotherapy-resis-
tant subtype that currently lacks targeted therapies.
Identification of novel genetic dependencies of SF3B1
driver mutations in breast cancer
Patty Wai, Sarah L. Maguire, Andri Leonidou, Helen Pemberton,
Barrie Peck, Christopher J. Lord and Rachael Natrajan
The Institute of Cancer Research
Mutations in SF3B1 that are involved in RNA splicing have been
found to occur at relatively high frequencies in several tumour types
and have been postulated as bona fide drivers. Our aims were to
investigate whether dysfunction in RNA splicing is implicated in
SF3B1 mutant breast cancers and whether tumours harbouring these
mutations could be therapeutically targeted.
Analysis of published exome, whole-genome and RNA-sequencing
data of[1000 primary tumours revealed hotspot mutations in SF3B1 are
preferentially associated with ER-positive disease (2 %) including a
higher frequency (up to 16 %) in some rare histological subtypes. Mas-
sively parallel RNA sequencing identified consistent patterns of aberrant
splicing in SF3B1 mutant tumours that are validated in a re-analysis of
RNA-sequencing data from The Cancer Genome Atlas (TCGA). Anal-
ysis of reverse phase protein array data from primary tumours
demonstrated that mutant tumours show perturbation of common onco-
genic signalling pathways, such as AKT and mTOR, rather than a
dependency ofmutant cells to individual alternatively spliced transcripts.
Importantly, cells harbouring SF3B1 mutations were selectively sensi-
tive to SF3b spliceosome complex inhibitors, and treatment of mutant
cells resulted in reversal of the aberrant RNA splicing signature.
We further investigated whether SF3B1 could be exploited thera-
peutically by performing a high-throughput drug screen utilising
isogenic cell lines harbouring the SF3B1K700E hotspot mutation. This
identified a number of lead compounds that selectively killed mutant
cells, including the AKT and mTOR inhibitors, further highlighting the
importance of these signalling pathways in mutant tumours.
Our findings indicate that mutations in SF3B1 are potentially
therapeutically tractable in breast cancers, and have identified a
number of potential genetic dependencies of oncogenic signalling
pathways in SF3B1 mutant tumours.
Survival and costs of postmastectomy radiotherapy
among N1 breast cancer patients: A propensity score-
matched study
Chihtao Cheng, Skye Hung-Chun Cheng, MD, Zhen-Ying Liu,
MPH, Yi-Ping Lin, MS, Lay-Chin Lim, MS
Koo Foundation Sun Yat-sen Cancer Center
Purpose/Objectives The St. Gallen Breast Cancer Conference 2015
found no consensus regarding the application of postmastectomy
radiotherapy (PMRT) in N1 breast cancer patients. This study
examined the effect of PMRT on the survival and medical costs of N1
mastectomy breast cancer patients.
Materials/Methods Taiwan Cancer Registry data and National
Health Insurance claims data were used to identify female patients
who were newly diagnosed with pT1-2N1 breast cancer between 2004
and 2009. Exclusion criteria included diagnosis of bilateral breast
cancer or metastatic disease, positive surgical margins, and radio-
therapy or chemotherapy before mastectomy. Of the 6422 patients
who met the inclusion criteria, 2926 (46 %) had PMRT and 3496
(54 %) did not. One-to-one propensity score matching was used to
control for potential confounding factors including age, comorbidi-
ties, pathological N and T stages, tumor grade, year of diagnosis, and
having received chemotherapy or hormone therapy.
Results In Kaplan–Meier analysis, we found the 5-year overall sur-
vival rates and disease-free survival rates in PMRT group were higher
than non-PMRT group (92.1 % vs. 90.1 %, p = 0.0072 and 79.3 %
vs. 73.8 %, p\ 0.0001), respectively. The PMRT group had signif-
icantly higher overall survival (hazard ratio (HR) = 0.79;
p = 0.0177; 95 % CI = 0.643–0.959) and disease-free survival
(HR = 0.75; p\ 0.001; 95 % CI = 0.664–0.857) compared with the
non-PMRT group. A mean net increase of 0.10 year in overall sur-
vival and 0.43 year in disease-free survival was observed. The mean
cost totals were US$16,559 for the non-PMRT group and US$20,778
for the PMRT group. An incremental cost-effectiveness ratio of
US$42,190 for overall survival and US$9812 for disease-free survival
per year gained was found in our analysis.
Conclusions PT1-2N1 breast cancer patients treated with PMRT
exhibited superior survival outcomes and an acceptable cost-effec-
tiveness ratio.
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Ganoderma applanatum - potential target for
stimulating macrophages in immunosuppressive breast
cancer microenvironment
Javed S.1, Payne G.W2, Lee C.H.1
1Biochemistry & Molecular Biology, 2Northern Medical Program,
University of Northern British Columbia, Canada
Natural products have been used as main ingredients of traditional
medicines for thousands of years. Breast cancer is the most common
cancer affecting women worldwide. Problems such as toxicity,
resistance, and nonspecificity of the target limit the use of
chemotherapy. This dilemma calls for the need to explore natural
ways to cure cancer by activating the immune system.
Macrophages, major immune cells, are one of the most abundant
and vital key players in the breast cancer microenvironment. They
play a critical role in each step from tumor initiation to its progression
and development. In the initial antitumour response, these macro-
phages release pro-inflammatory cytokines such as interleukin 6 (IL-
6), tumour necrosis factor alpha (TNF-a), etc., which are helpful in
destroying breast cancer cells. However, in chronic inflammatory
stages, these macrophages get switched to tumour-associated mac-
rophages (TAMs) which are more inclined towards anti-inflammatory
and immunosuppressive response, consequently inhibiting the ten-
dency of the body to fight against the tumours. These suppressed
macrophages could be a potential target for anticancer therapy as,
with the help of stimulation, these can regain their power to kill
tumour cells.
The current study aims to investigate the effects of Ganoderma
applanatum, a wild mushroom of British Columbia, Canada. This
mushroom experienced sequential extraction with the help of four
solvents: 80 % ethanol, 50 % methanol, water, and 5 % NaOH. These
extracts were then tested on RAW 264.7 macrophage cells for their
ability to stimulate TNF-a production. The results showed that water
extract of Ganoderma applanatum demonstrated the most effective
stimulatory activity (more than 100 % as compared to the positive
control Lipopolysaccharide). The promising novel immunostimula-
tory activity from this wild mushroom suggests the need for further
purification and identification of bioactive molecules which could be
used in the treatment of breast cancer.
GPR89A/GPHR is associated with the secretory
pathway and is a novel oncogene in breast cancer
Riccardo Ferro1, Pierfrancesco Marra1, Sumi Mathew,
Alessandra Facchetti, Gianfranco Picco, Patrycja Gazinska,
Farzana Noor, Claire Shooter, Priyanka Ghongane, Yanan Zhu,
Daniel Weekes, Elodie Noel, Hasan Mirza, Mamun Rashid,
Emanuele de Rinaldis, Fara Brasó Maristany, Jelmar Quist,
Anita Grigoriadis and Andrew Tutt
Breast Cancer Now Research Unit, Department of Research
Oncology, Guy’s Hospital King’s College London School
of Medicine, London SE1 9RT, UK; 1Equal contribution
Aims To characterise the functional role and the suitability as targets
for therapy of amplified and overexpressed genes, specifically
GPR89A/GPHR, a protein upregulated required for breast cancer cell
lines (BCCLs) growth
Procedures Previous analyses of the gene copy-number (CN) alterations
and gene expression profiles in a Triple-Negative Breast Cancers
(TNBCs)-enriched cohort of tumour samples identified 141 genes
specifically upregulated in tumour with pre-specified features suggesting
suitability as drivers of potentially targetable malignant phenotypes.
siRNA-based functional validation selected 33 genes specifically required
byBCCLs for cell growth. GPR89A/GPHRhas been further characterised
for its mechanisms of malignant cell-specific addiction.
Major Findings GPR89A/GPHR is amplified and highly expressed in
our cohort (60 % of breast cancers overall and 60 % of TNBCs) and
in publicly available datasets such as TCGA. GPR89A/GPHR is
required for cancer cell proliferation while redundant in non-malig-
nant cells. Published evidence suggests GPR89A/GPHR to be a
proton pump controlling the pH of the Golgi complex. Additional
evidence, in plants, suggests high similarity (65 %) and identity
(45 %) with the Abscisic Acid receptor, a G-protein-coupled receptor,
controlling intracellular calcium levels. Our data in BCCLs suggest an
Endoplasmic Reticulum (ER) localisation of GPR89A/GPHR, which
controls the dynamics/post-translational modification of plasma
membrane (PM) proteins such as EGFR, IL15RA and MUC1. GPR89
KD causes a reduction in the levels of pERK1/2 and an accumulation
in the S-phase of the cell cycle.
Conclusion GPR89A/GPHR is upregulated in breast cancer and
aberrantly localised to the ER where it controls the Post/translational
modification and dynamics of PM proteins and signals through ERK1/
2 controlling cell cycle and proliferation.
Significance As GPR89A/GHPR is required for proliferation of
BCCLs is redundant in non-malignant cells and is potentially druggable
as either aGPCRor an ion channel, it shows potential as a suitable target
for therapy in breast cancer particularly those with TNBC.
An integrated genomics and RNAi approach identifies
the KIFC1 kinesin as a selective target for triple-
negative breast cancer with centrosome amplification
Nirmesh Patel, Daniel Weekes, Elodie Noel, Konstantinos
Drosopoulos, Emanuele de Rinaldis, Mamun Rashid, Hasan
Mirza, Fara Brasó-Maristany, Sumi Mathew, Erika Francesch
Domenech, Patrycja Gazinska, Farzana Noor, Jelmar Quist,
Rebecca Marlow, Anita Grigoriadis, Spiros Linardopoulos,
Pierfrancesco Marra, Andrew Tutt
Breast Cancer Now Research Unit, Guy’s Hospital, King’s College
London
Background Triple-negative breast cancers (TNBCs) have limited
targeted treatment options. Large-scale genomic and transcriptomic
studies have advanced our understanding of TNBCs. However, the
substantial number of copy number and gene expression alterations in
TNBCs makes it difficult to identify putative drivers, biomarkers and/
or therapeutic targets of the disease. To overcome this problem, we
have carried out an integrative computational and RNAi-based
approach to identify TNBC gene addictions.
Methods Copy number and gene expression alterations in a large
breast tumour series enriched for TNBCs were analysed with normal
breast controls revealing 141 candidate genes whose upregulated gene
expression is copy number driven in TNBC. Of these, RNAi-based
functional validation revealed 33 malignant cell-specific addiction
genes using an array of breast cancer and non-malignant cell lines.
Results STRING analysis of validated hits reveals a subset of genes
involved in mitosis. We further validated KIFC1 (HSET) which is
known to play a role in clustering supernumerary centrosomes, a
common occurrence in breast cancer. We show that siRNA and
shRNA-mediated depletion of KIFC1 decreases cell viability and
clonogenic ability specifically in centrosome-amplified cell lines,
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which can be rescued upon introduction of an si/shRNA resistant
KIFC1. KIFC1 depletion also produces a high level of catastrophic
multipolar mitoses specifically in centrosome-amplified cell lines.
Furthermore, in vivo studies show that depletion of KIFC1 suppresses
tumour growth of centrosome-amplified cell line xenografts.
Discussion We identify and functionally validate novel tumour
addiction genes in TNBC. Our data show that KIFC1, a druggable
kinesin motor protein, is a promising malignant cell-selective target for
therapy expressed in a significant proportion of TNBCs.We validate its
cancer-specific role in amplified centrosome clustering showing that
KIFC1 plays an essential role in aiding the survival of breast cancer cells
that have supernumerary centrosomes both in vitro and in vivo.
Metformin: a new role in breast cancer prevention?
Caitriona Tyndall1, Marc Gunter2,3
and James M. Flanagan1
1Epigenetics Unit, Department of Surgery and Cancer, Imperial
College London, UK; 2Department of Epidemiology & Biostatistics,
School of Public Health, Imperial College London, UK; 3Nutritional
Epidemiology Group, International Agency for Research on Cancer
(IARC), France
Breast cancer is the most commonly diagnosed cancer in the UK,
accounting for 7 % of overall cancer death. Metformin is a biguanide
drugused to treat Type IIDiabetesMellitus and has been shown to reduce
breast cancer risk by up to twofold in diabetics, particularly in long-term
users. Metformin activity leads to metabolic stress, reduced growth sig-
nalling and cell death. Themechanisms ofmetformin action in relation to
breast cancer are largely unknown. This study aims to investigate how
metformin activity modulates normal breast epithelial cell growth and
proliferation to provide insight into the mechanisms by which it may
prevent breast cancer. We have conducted a comparison of metformin
treatment in 2Dand3Dcell culture using twonormal breast epithelial cell
lines, MCF10A andMCF12A.We have validated metformin activity by
RT-qPCR andWestern Blot for known targets including AMPK, mTOR
and CyclinD1. We used MTT cell viability assays to assess cell survival
in response to increasing doses of metformin after 3 and 7 days of
treatment. We observed marked differences in response to metformin
treatment between the two cell lines, withMCF12A being more resistant
in 2Dculturewith an IC50of 6 mM, comparedwith an IC50 of 3 mMfor
MCF10A after 7 days (ANOVA, p\ 0.0001). Furthermore, 3D culture
indicates increased drug sensitivity and reduced mammosphere forma-
tion, suggesting that long-term exposure to metformin is instigating
marked changes in normal breast epithelial cell function. In summary,
this study has shown that normal breast epithelial cells are sensitive to
metformin treatment. Future work aims to investigate the hypothesis that
long-term use of metformin may be eliciting stable molecular changes
that may persist adding to its protective effects.
Sulforadex targets breast cancer stem-like cells in
patient-derived cells and xenograft tumours
Bruno Simões, D. Alferez, R. Eyre, K. Spence,
A. Santiago-Gomez, A. Sarmiento-Castro, I. Tanaka,
B. Kohler, D. Howat, S. Howell, R. Clarke
University of Manchester
Sulforadex (SFX) is a novel therapeutic comprising synthetic sul-
foraphane (SFN) stabilised within alpha-cyclodextrin. SFN has been
studied as an anti-cancer compound for many years; however, its
development has hitherto been hampered due to its inherent insta-
bility. Breast cancer stem-like cells (CSCs) have been identified in all
molecular subtypes and are believed to be the drivers of breast cancer
metastasis.
We investigated SFX effects on breast CSC activity using mam-
mosphere formation and aldehyde dehydrogenase (ALDH) activity in
patient samples and patient-derived xenograft (PDX) tumours. SFX
(5 lM) induced a significant reduction in the mammosphere formation
efficiency of both primary (67 %, n = 8/12) and metastatic (80 %,
n = 12/15) patient cells. Importantly, using a 14-day in vivo ‘window’
treatment, SFX (300 mg/Kg/day) also abrogated breast CSC activity of
early (HBCx34) and metastatic (BB3RC31) PDX tumours.
The majority of breast cancers express the oestrogen receptor (ER)
but these hormone-responsive breast cancers frequently develop
resistance to endocrine therapies (e.g. tamoxifen). We have established
that CSCs in ER+ breast cancer lack ER expression, representing a
potential mechanism of therapeutic resistance (Simões et al., Cell
Reports, 2015). However, SFX targets such surviving CSCs identified
by ALDH positivity and mammosphere-initiating capacity following
tamoxifen treatment in vivo in ER+ HBCx34 and BB3RC31 PDX
tumours. In ongoing PDX experiments, which comprise endocrine
therapy in combination with SFX for a period of 8 weeks, we will test
the effects of the combination on tumour regression.
Mechanistically, SFX inhibited the canonical Wnt pathway in
MCF-7 cells and their endocrine-resistant derivatives and we are
currently exploring SFX activity on other CSC regulatory pathways.
Our data demonstrate the potential of SFX for clinically mean-
ingful improvements to endocrine therapy in ER+ breast cancer by
reversing CSC-mediated resistance.
Molecular mediators of mammographic density
Alastair Ironside, Jenny Gomm, Linda Haywood, Iain Goulding,
Jun Wang, Claude Chelala, J. Louise Jones
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary
University of London
IntroductionMammographic density (MD), created predominantly by
increased stromal tissue, is a major risk factor for the development of
breast cancer, though little is known about the biological mechanisms
mediating it. Tamoxifen prevents breast cancer in a subset of high-risk
women via mechanisms that appear dependent on reduction of MD.
Animal models suggest tamoxifen remodels the mammary stroma to a
tumour-inhibitory phenotype. This study aims to analyse the effect of
tamoxifen on breast fibroblast function and identify pro-tumourigenic
pathways contributing to the density-associated risk.
Methods Primary human breast fibroblasts from normal, high-risk or
breast cancer patients were treated with hydroxytamoxifen (4-
OHTam, 100 nM-5uM), the active metabolite of tamoxifen. Fibrob-
last function was analysed by measuring: proliferation, expression of
stromal proteins fibronectin, LOX and collagen 1; effects on TGF-b
signalling via SMAD phosphorylation and upregulation of the
myofibroblast marker SMA. Genome-wide analysis was performed
using RNA-Seq.
Results Fibroblasts from 25 patients were treated with 4-OHTam. All
patients showed reduced proliferation with treatment. 62 % of
patients showed reduced fibronectin expression. TGF-b-mediated
upregulation of SMA and fibronectin was consistently inhibited.
RNA-Seq analysis revealed significant downregulation of Wnt sig-
nalling, an established pro-fibrogenic and pro-tumourigenic pathway,
and modulation of many metabolic pathways, including components
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of the microsomal anti-oestrogen binding site (AEBS). Binding of
tamoxifen to the AEBS inhibits ChEH activity promoting an anti-
tumourigenic phenotype. The effects of tamoxifen on fibroblasts
could be replicated using tesmilifene, a commercially available
inhibitor of ChEH.
Conclusion These data indicate that tamoxifen can directly remodel
the stromal microenvironment, generating a less ‘reactive’ stroma.
Thus, tamoxifen impacts on multiple pathways, many independent of
the oestrogen receptor, to create a tumour-inhibitory microenviron-
ment. This offers exciting potential for patient monitoring and
alternative breast cancer prevention strategies.
The effect of cyclopamine on hedgehog signalling
pathway in breast cancer cells
Arwa Flemban, David Qualtrough
University of The West of England, Umm Al-Qura University
Introduction Breast cancer in the second leading cause of death in
women worldwide, with a risk of 1 in 8 women developing this disease
at some point in their lives. Breast cancer is also the most diagnosed
cancer in females.Most deaths associatedwith this illness are caused by
metastasis. Cancer metastasis involves the process of epithelial–mes-
enchymal transition (EMT) and understanding this process and its
regulatory mechanism in breast cancer could propose answers of the
disease prognosis, thereby identifying possible targets for therapy.
Hedgehog (Hh) signalling pathways were found to be involved in
in vivo and in vitro studies of human cancers. It is suggested that mis-
appropriation of Hh pathway is involved in breast neoplasia and cancer
stem cell and breast tumour cellmetastases. Yet, the involvement of this
pathway in breast cancer subtypes remains poorly understood.
Aims The current study aimed to investigate the effect of cyclopa-
mine, a plant-derived alkaloid inhibitor of Hh, on cellular yield,
apoptosis, EMT, and Hh markers’ expression (E-cadherin, b-catenin,
Gli1, Gli2, and Gli3). Moreover, localisation of these markers was
also assessed in breast cell lines.
Procedures Breast cancer cell lines MCF7, MDA-MB361 (Luminal),
BT20, MDA-MB-231 (Basal and Triple-negative), MDA-MB-453,
and SKBR3 (HER2+ ve) were used in this study. In addition, normal
breast cell line (MCF10A) was also included. These cells were treated
with three concentrations of cyclopamine (1, 5, and 10 M) for 48 h
and compared with untreated cells. Cell apoptosis was evaluated by
Annexin V kit. Moreover, the expression of E-cadherin, b-catenin,
Gli1, Gli2, and Gli3 in these cells was assessed by immuno-cyto-
fluorescence and flow cytometry.
Major findings Cyclopamine reduced cell number and induced cell
apoptosis in a dose-dependent manner; this reduction was depending on
the type of breast cancer cell line. Additionally, cyclopamine decreased
the expression of Gli and changed its nuclear localisation. E-cadherin
expression increased in some of the breast cancer cells after treatment,
and there was a reduction in the level of b-catenin expression.
Significance of the research and Conclusions The present study
demonstrated that the expression of Gli markers varied according to
the type of breast cancer and the level of expression and localization
of Gli changed after treatment with cyclopamine. The data indicated
Hh signalling pathway involved in breast neoplasia and the misap-
propriation in Hh signalling differed according to the subtype of
breast cancer. That also indicated that cancerous cells response to
cyclopamine treatment varies according to subtypes.
Evaluating the Estimated Lifetime Oestrogen Exposure
(ELEE) model as a risk factor for breast cancer
Annelie Johansson1, EPIC-Italy Investigators, Paolo Vineis2,3,
and James M. Flanagan1
1Epigenetics Unit, Department of Surgery and Cancer, Imperial
College London, UK; 2MRC/PHE Centre for Environment
and Health, School of Public Health, Imperial College London, UK;
3Human Genetics Foundation, Torino, Italy
It is well established that oestrogen levels are involved in the
aetiology of breast cancer. Numerous hormonal risk factors have
been separately well studied and shown to increase risk, including
early menarche, late menopause, nulliparity, later age at first full-
term pregnancy, oral contraceptives, hormone replacement therapy,
and increased BMI for postmenopausal women. How these factors
interact and combine to affect breast cancer risk, however, has been
less well characterised. We aimed to develop a mathematical model
to estimate a woman’s lifetime exposure to oestrogen based on
hormonal risk factors. We used a case–control study design nested
within the European Prospective Investigation into Cancer and
Nutrition (EPIC) Italy cohort (n = 710 postmenopausal breast can-
cer cases matched with 2 controls per case, n = 1420). For each
hormonal risk factor, the odds ratio (OR) was estimated using
conditional logistic regression analysis. The first Estimated Lifetime
Oestrogen Exposure (ELEE) model was calculated simply as the
reproductive time between menarche and menopause. We observed
a 12 % increased breast cancer risk for each additional year to a
woman’s reproductive time (OR = 1.12, 95 % Confidential Interval
(CI): 1.00–1.25). Parity shortens the reproductive time and was
subtracted from the reproductive time in the second ELEE model,
and the z-score of BMI was added since it showed a strong asso-
ciation with increased breast cancer risk (OR = 1.04, 95 % CI:
1.02–1.06) within the dataset. This modified ELEE model was
further associated with breast cancer risk (OR = 1.14, 95 % CI:
1.06–1.22). The introduced ELEE models support the association
between oestrogen exposure and increased risk for breast cancer,
and we conclude that the reproductive time, parity, and BMI in
combination are a valid approximation for a woman’s total oestro-
gen exposure. Future studies will focus on developing the ELEE
model in premenopausal women and introduce other hormonal and
lifestyle risk factors.
Developing a decision aid around genetic testing
for young women with breast cancer—the YoDA BRCA
Study
Grimmett C.1, Brooks C.1, Recio-Saucedo A.1, Cutress R.2,
Copson E.2, Evans G.D.3, Gerty S.2, Armstrong A.4, Turner L.5,
Mason S.5, Ahmed M.6, Eccles B.2, Eccles D.7, and Foster C.1
1Macmillan Survivorship Research Group, Faculty of Health
Sciences, University of Southampton, Southampton, UK; 2Cancer
Sciences, University of Southampton, Southampton, UK; 3Genetic
Medicine, University of Manchester, UK; 4Christie Hospital NHS
Trust, Manchester, UK; 5Patient and Public Involvement; 6Wessex
Clinical Genetic Service, Southampton, UK; 7University
of Southampton, Clinical Trials Unit, UK
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Background Younger women diagnosed with breast cancer are more
likely to have inherited genetic mutations. Genetic testing around the
time of diagnosis is becoming more common with genetic testing
being increasingly offered to inform treatment decisions. Information
to support decision making for young women is often unavailable
outside of specialist genetics services. Decision aids (DA) can support
women to make informed choices.
Aim To explore the views and experiences of young women about
genetic testing and their information preferences to inform the
development of a web-based DA.
Methods Participants were B 50 years and B 18 months of diagnosis
and recruited from two NHS hospitals. Purposive sampling ensured
inclusion of women with a range of characteristics relating to genetic
testing. Semi-structured interviews and focus groups were employed.
Verbatim transcripts were interrogated using a framework approach.
Results 29 women participated in interviews; 15/29 women had
undergone genetic testing (N = 3 BRCA-positive results). The fol-
lowing themes emerged as important for decision making regarding
genetic testing: personal attitudes/values regarding genetic testing;
knowledge of reasons to have/not have testing, test processes and
implications of testing for themselves and family members. Clear
‘jargon-free’ information was desired and level of information prefer-
ences varied within and between individuals. Two focus groups (N = 7
in each) highlighted the importance of a summary of each area of
interest, followed by further information, warnings prior to accessing
sensitive information and avoiding terms such as ‘faulty’ gene’.
Conclusion Findings from the interviews and focus groups will be
used to develop a prototype DA to be refined in think-aloud inter-
views. The final DA will endeavour to support decision making
regarding whether or not to have genetic testing. Future research will
include testing the finalised DA in a randomised controlled trial.
Defects in ARID1A and other BAF complex tumour
supressor genes sensitise tumour cells to clinical
inhibitors of the DNA damage checkpoint kinase, ATR
Chris Williamson
The Institute of Cancer Research
Identifying genetic biomarkers of synthetic lethal drug sensitivity
effects provides one approach to the development of precision
medicine treatments for cancer. Mutations in BAF complex tumour
suppressor genes represent one of the most common molecular
alterations in human cancer. However, therapeutic approaches that
selectively target BAF defects are not yet clinically available. Here
we demonstrate that defects in ARID1A and other BAF complex
tumour suppressor genes sensitise tumour cells to clinical inhibitors
of the DNA damage checkpoint kinase, ATR, both in vitro and
in vivo. Mechanistically, ARID1A deficiency results in topoiso-
merase 2A and DNA decatenation defects, which cause an increased
reliance on ATR checkpoint activity. In ARID1A mutant tumour cells,
inhibition of ATR triggers premature mitotic entry, genomic instability
and apoptosis. ATR inhibitors are currently in Phase I clinical trails as
combination therapies. The data we present here provides the preclin-
ical and mechanistic rationale for assessing BAF defects as biomarkers
of single-agent ATR inhibitor response and represents a novel synthetic
lethal approach to targeting tumour cells.
Bisphenol A alternatives can effectively
substitute for estradiol in promoting cell growth
through estrogen receptors in human breast cancer
cells
Robin Mesnage, Alexia Phedonos and Michael
N. Antoniou
Gene Expression and Therapy Group, King’s College London,
Faculty of Life Sciences & Medicine, Department of Medical
and Molecular Genetics, Guy’s Hospital London
Background Plasticizers with estrogenic activity, such as bisphenol
A (BPA), have been reported to have potential adverse health effects
in humans, especially in fetal and infant stages. Due to mounting
evidence and public pressure, BPA is being phased out by the plastics
manufacturing industry and is being replaced by other bisphenol
variants in ‘‘BPA-free’’ products. We have compared estrogenic
activity of 7 bisphenol analogs (BPA; bisphenol S, BPS; bisphenol F,
BPF; bisphenol AP, BPAP; bisphenol AF, BPAF; bisphenol Z, BPZ;
bisphenol B, BPB).
Methods Activation of estrogen receptors was determined using a
mammary T47D cell line harboring a stably integrated copy of a
luciferase reporter gene under control of a promoter containing
estrogen response elements. Cell proliferation induced by the acti-
vation of estrogen receptors was determined in three breast cancer cell
lines (MCF-7, T47D, and MDA-MB-231) by the conventionally used
E-screen assay. The natural hormone estradiol was used as a
reference.
Results All bisphenols were able to substitute for the natural hormone
in promoting cell growth through estrogen receptors. In both assays,
BPAF was most potent bisphenol (50 % effective concentration for
receptor activation = 0.08 lM) followed by BPB (0.3 lM)\BPZ
(0.4 lM) * BPA (0.4 lM)\BPF (1 lM) * BPAP (1 lM)\BPS
(3 lM). The addition of ICI 182,780 (100 nM) antagonized the
activation of estrogen receptors by both estradiol and bisphenols.
Conclusions Our results show that BPA-free products are not nec-
essarily safer. Three bisphenols (BPAF, BPB, BPZ) were more
estrogenic than BPA. The clinical relevance of human exposure to
BPA alternatives in hormone-dependent breast cancer progression
should be investigated.
Restricted glycolysis promotes stem cell-like
characteristics in breast cancer cells
Arindam Banerjee, P. Arvinrad, M. Darley, Stephanie Laversin,
Ramsey Cutress, Stephen Beers, Franchesca Houghton, Charlie
Birts and Jeremy Blaydes
Cancer Sciences, Faculty of Medicine, University of Southampton,
United Kingdom
Increased glucose uptake is a characteristic feature of many cancer
cells, including those from breast tumours. However, during cancer
progression and metastasis, cancer cells can modulate their glucose
utilisation to overcome localised nutritional limitations in hostile
microenvironments. We hypothesised that this plasticity in glucose
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utilisation could result in changes in the cells’ oncogenic potential. To
investigate this, we established a panel of human breast cancer cell
lines containing matched pairs with either standard (i.e. high) or
reduced rates of glycolysis. Glycolysis was reduced by adapting cells
to grow in 10 mM fructose, compared to the standard 25 mM glucose.
Next, we investigated the cells’ oncogenic potential by various cell
function-based studies (3D matrigel assay and cell invasion assay) in
in vitro conditions. Furthermore, we also determined whether gly-
colytic rates influence any changes in the cancer stem cell-like (CSC)
population by specifically identifying their mammosphere- forming
ability and changes in the CD44high/CD24low/-ve and ALDH1 + ve
cell populations. Significant increases in growth in 3D matrigel, cell
invasion, and the proportion of cells with CSC-like properties were
observed across all the glycolytically restricted cells, compared to
their glycolytic counterparts. Hence, metabolic adaptation of breast
cancer cells to glucose-restricted conditions results in more invasive
and stem cell-like features. Molecular identification of key molecules
involved in this process is ongoing, as we anticipate that they may
include potential prognostic biomarkers and/or therapeutic targets.
Modelling MCL-1 inhibition in breast cancer
Kirsteen Campbell, Sandeep Dhayade, Nicola Ferrari, Emma
Johnson, Jane Hair, Joanne Edwards, Stephen Tait and Karen
Blyth
Beatson Institute
Aims To test the hypothesis that MCL-1 is required for both the
development and maintenance of breast cancer and to investigate the
therapeutic potential of MCL-1 inhibition in breast cancer.
Procedures Approaches used include in silico analysis of MCL-1
expression in publicly available datasets and immunohistochemistry
on breast tumour tissue microarrays. Small-molecule MCL-1 inhibi-
tors and knock-down/knock-out of MCL-1 in in vitro and in vivo
models were also used to investigate the therapeutic potential of
targeting MCL-1 in breast cancer.
Major findings We find that MCL-1 is frequently elevated in breast
cancer. Strikingly, this is most prominent in the basal subtype,
regarded as the most stem cell-like of the molecular classifications
that is both highly aggressive and has limited therapeutic options.
Moreover, we find high expression of MCL-1 protein in human breast
cancer tissue samples, especially in ER-negative disease, and find
associations between high MCL-1 and poor prognosis. We show that
inhibition or knock-down of MCL-1 in breast cancer cell lines in vitro
and in vivo impairs tumour growth, and we are now using GEM
models to further investigate the role of MCL-1 in breast cancer
development and response to therapy.
Significance of research Inhibition of anti-apoptotic BCL-2 function,
using drugs called BH3-mimetics, shows considerable promise in the
treatment of haematological malignancies. Drugs specifically target-
ing the BCL-2 family member MCL-1 are under development, and
our data suggest that these will have the potential to improve the
treatment of breast cancer.
Conclusions ElevatedMCL-1 is associated with poor prognosis in breast
cancer and MCL-1 inhibition may provide a new therapeutic approach.
Characterisation of a new mechanism of ATR/Chk1
regulation in breast cancer: role of mTORC2
Jogitha Selvarajah, Veronica A. Carroll
St George’s, University of London
mTOR is a serine–threonine kinase belonging to the PIKK family and
acts as a central node to integrate signalling from growth and stress
factors to regulate cell growth. Other members of the PIKK family are
ATM,ATR andDNA-PKcs, which all have established roles in theDNA
damage response. mTOR is the catalytic component of functionally
distinct complexes mTORC1 and mTORC2. Recent data show that
mTORC2 complex also has tyrosine kinase activity. Dysregulation of
mTOR signalling occurs in numerous cancers, particularly in breast
cancer, leading to the use of mTORC1 inhibitors such as the rapamycin
analogue (rapalog), everolimus, for advancedhormone receptor-positive,
HER2-negative breast cancer in combinationwith exemestane. There are
manyongoing clinical trials of rapalogs in combination therapy including
DNA-damaging agents to treat breast cancer as well as mTOR kinase
inhibitors that target both mTORC1 and mTORC2 complexes. Using
breast cancer cell lines and biochemical methods, we have recently
demonstrated that there is significant crosstalk between the nutrient and
stress sensing mTOR pathway and the DNA damage response activation
ofATR/Chk1.We recently demonstrated thatDNAdamage-induced cell
cycle arrest at S and G2/M phase is dependent on mTOR. Specifically,
mTORC2 was required for the activation of Chk1, a key cell cycle reg-
ulator, at the level of Chk1 protein production. Furthermore, in a panel of
breast cancer cell lines, with varying degrees of chemoresistance, an
mTOR kinase inhibitor was able to overcome resistance to DNA-dam-
aging agents by potentially destabilising cell cycle arrest and thereby
enhancing DNA damage-induced cell death. These data suggest that
mTORC2-Chk1 signalling is a survival pathway in breast cancer which
has important implications for breast cancer combination therapy.
Functional investigation of a putative breast cancer risk
variant
Joe Baxter, Nicola H. Dryden, Laura R. Broome, Nichola
Johnson, Sarah L. Maguire, Nick Orr, Olivia Fletcher
The Institute of Cancer Research, London
Two independent tagging SNPs (rs13387042, rs16857609), mapping to
2q35, have been strongly associated with increased breast cancer sus-
ceptibility. For one of these (rs13387042), fine-mapping and functional
studies have identified a putative causal variant which influences
FOXA1 binding to a transcriptional enhancer of IGFBP5. To identify a
second putative causal variant, we made the following assumptions:
(i) this causal variant would be correlated with rs16857609, (ii) it would
be associated with levels of expression of IGFBP5, and (iii) it would
physically interact with IGFBP5 to influence expression.
We identified 106 SNPs that were correlated (r2[ 0.2) with both
rs16857609 and an IGFBP5 eQTL SNP (rs6716223). Of these, 8 also
mapped to a region within the 2q35 locus that formed long-range
([700 kb) physical interactions with the IGFBP5 promoter, based on
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Capture Hi-C interaction data. Consulting breast-relevant ChIP-seq
(FOXA1, GATA3, ER-a) and DNase-seq data, we were able to
identify a single SNP that maps to a region exhibiting characteristics
of a functional element—rs78040234.
Regulatory properties of the region were first assessed by luci-
ferase reporter assay. In the context of the IGFBP5 promoter, the
region containing rs78040234 significantly upregulated the expres-
sion of the reporter (p\ 0.001); moreover, a single-nucleotide
substitution of rs78040234 to the minor, risk-associated allele reduced
the upregulatory activity (p = 0.02). We are currently generating
breast cancer cell lines with deletions and substitutions in the
rs78040234 region to investigate the functional element and the role
of the SNP in an endogenous context.
Translocation-induced gene breakage identifies
recurrent fusion gene candidates
Aisyah Mohd Noor1, Sarah Maguire2, Johnathan Watkins1,
Jelmar Quist1, Hasan Mirza1, Kayleigh Ougham1, Andrew Tutt1,
Cheryl Gillett3, Rachael Natrajan2, Anita Grigoriadis1
1Breast Cancer Now Research Unit, Guy’s Hospital, King’s College
London, London SE1 9RT, UK; 2Breast Cancer Now Research
Centre, Institute of Cancer Research, London SW3 6JB UK; 3King’s
Health Partners Cancer Biobank; Research Oncology, Guy’s Hospital,
King’s College London, London SE1 9RT, UK
Breast cancer is characterised by widespread structural and chromo-
somal rearrangements and fusion genes that influence transcription,
leading to aborted transcription, gene inactivation or gene activation.
We aimed to identify disrupted transcripts with underlying genomic
alterations and characterise their features in breast cancers.
Affymetrix SNP6.0 and Exon1.0ST data of 123 in-house primary
breast tumours were analysed with a walking Student’s t test to identify
disrupted transcripts with proximal genomic breakpoints. SNP6, exon-
array and RNA-seq data of 51 breast cancer cell lines (BCCL) and 152
BRCA samples from The Cancer Genome Atlas (TCGA) were used for
validation. Fusion transcripts were detected using the ChimeraScan
algorithm. Samples were molecularly characterised by immunohisto-
chemistry for hormone receptors (ER and PR), PAM50, IntClust and
TNBC subtyping, genomic instability measures, and gene signatures.
We identified 106 out of 877 disrupted transcripts with proximal
genomic breakpoints, and recurrent in at least five samples. RNA-seq of
BCCL and TCGA data depicted 33/106 as gene fusion partners. Thirty-
one transcripts show putative oncogenic roles in literature and 26 were
found as potential fusion partners in breast cancers. While 20 transcripts
had diverse fusion partners, 13 transcripts consistently fused to unique
partners (range = 2–31, median = 3). Three novel fusions were recur-
rent across all datasets with multiple junction-spanning and uniquely
aligned reads (CDK14:CLDN12, n = 6; FOXP1:EIF4E3, n = 10;
lncRNA BC090059:RIN2, n = 89). IHC receptor subtype specificity
was observed for 7/33 aborted transcripts. Aborted transcription of
CDK14 and FRMD5 was more prevalent in PAM50-Luminal A and
HER2 samples, respectively. Overall aborted transcription was less
prevalent in the TNBC-LAR subtype (Fisher’s p value: 0.034).
We show that integration of exon expression and copy number
data can identify genes with disruption in their transcriptional units,
some of which represent fusion genes. Characterisation of these
transcripts, their partners and their prevalence with certain molecular
features can provide further knowledge to their biological significance
in breast cancers.
Identification of HORMAD1-induced synthetic
sensitivities in triple negative breast cancers
Dalia Tarantino, Dan Weekes, Helen Pemberton, Jessica
Frankum, Chris Lord, Jelmar Quist, Anita Grigoriadis,
Andrew Tutt
Breast Cancer Now Research Unit, Guy’s Hospital, King’s College
London
Triple-Negative Breast Cancers (TNBCs) are characterised by high
levels of genomic instability driven by DNA repair deficiencies.
HORMAD1, normally only expressed in germline cells, was found to
be present in *60 % of TNBCs and can induce genomic instability
through inhibition of DNA repair by Homologous Recombination.
The genes and pathways modulated in response to HORMAD1
expression in mitotic cells are currently unknown, but represent
potentially targetable synthetic sensitivities in TNBC.
To identify such pathways, an isogenic inducible HORMAD1-
expressing triple-negative breast cancer cell line SUM159 clone and
its parental isogenic control clone were screened with an RNA
interference library consisting of pools of 4 oligos targeting 1743
genes, including kinases, oncogenes, tumour suppressors and epige-
netic-related genes. Cell viability was evaluated with CellTiter-Glo.
Sensitising hits were validated in a secondary deconvolution screen
and in two GFP-expressing SUM159 clones to exclude sensitivities
caused by ectopic protein expression alone.
Our siRNA screen identified 63 genes which induced high levels
of sensitivity upon HORMAD1 expression and showed an enrichment
in genes involved in DNA repair. Out of those, 14 were tested and
eight genes were validated as having an on-target effect. Furthermore,
for 7 of these genes, namely XRCC1, TDP1, DCLRE1A, POLH,
NTHL1, BRIP1 and ATR, HORMAD1-induced sensitivity was con-
firmed in 2 additional HORMAD1-inducible expression clones.
Our data indicate that pathways that prevent replication fork
stalling or involved in their restart such as base excision repair
(XRCC1), DNA interstrand cross-link repair (DCLRE1A, FANCC)
and translesion synthesis (POLH) are involved in the tolerance of
HORMAD1 expression in mitotic cells. These compensatory DNA
repair mechanisms represent potentially targetable pathways in
HORMAD1-expressing TNBC and warrant further exploration.
Dissecting cancer cell metabolism in a 3D breast model
Caroline Barker, Papadakis, E.S., Cutress, R.,
Blaydes, J.P
University of Southampton
Glycolysis and fatty acid oxidation are being targeted therapeutically in
cancer, as these metabolic pathways are upregulated in cancer cells. The
breast can be modelled in 3D using an MCF-10A acini model, with
oncogene overexpression (MCF-10A:HER2) altering acinar morpho-
genesis to mimic DCIS, a breast cancer precursor. We have published
these models and their relevance for the study of pharmacological inhi-
bition; here we specifically examine the effect of molecular and
pharmacological alteration of metabolism onMCF-10Amorphogenesis.
To disrupt the cellular metabolic sensor machinery, pooled pop-
ulations overexpressing CtBP2 were generated by retroviral
transduction. To study the sensitivity of our models to therapeutic
agents, acini were cultured in 3D for 12 days, with metabolic
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inhibitors present from day 6. Acinar morphogenesis was studied
using confocal microscopy. 2D cell viability was assessed by ATP
and Alamar blue assays. All results are from three independent
experiments each containing three technical replicates.
Overexpression of the metabolic sensor CtBP2 interferes with
acinar morphogenesis (p B 0.001), promoting transformation. This is
reversible by CtBP inhibition. The metabolic inhibitors etomoxir
(p B 0.001) and oxamate (p B 0.01) reversed HER2-driven trans-
formation of acini. Dichloroacetate had no effect on MCF10A:HER2
acini but strikingly drove controls towards a transformed phenotype
(p B 0.001). In 2D cultures, oxamate inhibited viability (p B 0.01)
while etomoxir and dichloroacetate did not.
Manipulation of metabolism altered the transformation of MCF-10A
acini, highlighting the relevance of metabolism in cancer. The identifi-
cation of a phenotype in 3D that was not observed in 2D reinforces the
importance of 3D culture systems to examine pharmacological agents.
The role of TP53 in determining breast tumour subtype
Kate Packwood, M. Sommerlad, G. T. Martland,
R. Pengelly, E. C. Shaw, J. P. Blaydes, J.C. Strefford,
G. J. Thomas, A. C. Bateman, D. M. Eccles
University of Southampton
Background A germline TP53 mutation predisposes to young breast
cancer and other tumours recognized clinically as Li–Fraumeni
Syndrome (LFS). We hypothesized that an inherited TP53 mutation is
important in driving a specific breast tumour subtype and that timing
of TP53 malfunction may be relevant to subtype.
Methods We collected 136 breast cancer formalin-fixed paraffin-em-
bedded (FFPE) blocks from TP53 mutation carriers. Morphological
review was performed by two independent pathologists. Tissue
microarrays were constructed from ductal carcinoma in situ (DCIS) and
tumour tissue. A 48-sample HaloPlex-targeted enrichment kit was used
to characterise the genetic landscape and investigate timing of TP53 loss.
Results Tumours were typically high-grade ductal tumours of no special
type, associated with widespread high-grade DCIS. HER2 overexpression
was found in 63 % of cases compared with 24 % of an age-matched cohort
(Copson et al. J Natl Cancer Inst. 2013 105(13):978–88.) There was a high
frequency of tumours containing a sclerotic, collagen-rich stroma (85 % of
cases) and a similar proportion stained positive for stromal a-smooth muscle
actin, indicating myofibroblast differentiation and suggesting activation of
TGF-b1 signalling. Moderate to strong tumour staining for integrin avb6
(an activator of latent TGF-b1) was present in 50 % of cases. Targeted
Next-Generation Sequencing (NGS) of tumour DNA confirmed the germ-
line mutation across cases, with a suggestive loss of heterozygosity (LOH)
of the wild-type TP53 allele. Somatic mutations in cancer genes including
PIK3CA, NOTCH1, ATM, ATR, AKT1 and ERBB2 were detected. TP53
status will be confirmed in the matched DCIS precursor lesion.
Conclusion This supports the hypothesis that a germline TP53
mutation strongly predisposes to HER2-amplified, high-grade tumour
subtype. TGFb signalling and LOH of WT TP53 are likely drivers in
LFS breast tumours. NGS is successful in identification of somatic
mutations in archival FFPE material.
Combining patient-matched diagnostic and
on-treatment biomarkers significantly improves
prediction of response to endocrine therapy
Andrew Sims, Arran Turnbull, Dominic Pearce, Yan Ping Lee,
Lorna Renshaw, Sonya Uddin, Anu Fernando, Hannah Webb,
Jeremy Thomas, Mike Dixon
University of Edinburgh
Background Identifying which breast cancer patients will recur on
endocrine therapy is a major challenge. Many multigene classifiers
are available for predicting prognosis. These are used at diagnosis to
determine whether adjuvant endocrine treatment alone is sufficient for
ER+ patients to remain disease free, or if additional therapy is
required. We developed a test measuring diagnostic IL6ST and a
2-week proliferation marker (either at transcript level or by
immunohistochemistry, which accurately predicts neoadjuvant
response (NR), recurrence-free survival (RFS) and breast cancer-
specific survival (BCS).
Methods We compared predictions using our test with established
clinicopathological markers or estimations of multigene classifier
scores (Oncotype DX, EndoPredict, Prosigna, MammaPrint) before
and/or on treatment with aromatase inhibitors (AIs). We analysed
diagnostic and 2 week biopsies from 3 patient cohorts: A: n = 73,
treated in Edinburgh with neoadjuvant (3 months) then adjuvant
letrozole, B: n = 44, treated at Royal Marsden with neoadjuvant
anastrozole (3 months), and C: n = 84, receiving 2 weeks of AIs
prior to surgery and in the adjuvant setting. NR was determined using
ultrasound and cohorts A and C had 10 years follow-up.
Results Prediction accuracy of NR at 3 months was poor (30–70 %)
with existing methods using either pre or on treatment measures
alone. The most accurate predictions all utilised IL6ST level at
diagnosis and a proliferation marker (MCM4 or Ki67) on treatment
(70–96 %). Improvements were also observed with outcome predic-
tion: p = 0.0005 (RFS) and p = 0.0002 (BCS) in series A and
p\ 0.0001 for both RFS and BCS in series C. Hazard ratios calcu-
lated using our test were significantly higher than with all other
methods tested either pre or on treatment.
Conclusions Measuring IL6ST at diagnosis and proliferation at
2 weeks outperforms all current predictive classifiers and clinical
tools for both short-term (NR) and long-term (RFS and BCS) out-
comes for AI therapy.
A 3D in vitro model of the human breast duct:
unravelling myoepithelial–luminal interactions
in breast cancer
Edward Carter, J.J. Gomm, L.J. Jones, and R.P. Grose
Barts Cancer Institute
The ducts of the human breast are composed of an inner layer of
luminal cells supported by an outer layer of myoepithelial cells. This
bilayer is critical for the normal function of the breast and breaks
down in cancer. During DCIS, once luminal cells have adopted a
cancerous disposition, the myoepithelial layer remains intact but is
subsequently lost in invasive cancer. Interrogating the myoepithelial–
luminal relationship in a physiomimetic setting is therefore critical for
understanding how breast cancers are able to progress from DCIS to
invasive cancer. However, currently no system exists which models
this bilayer structure in a manner that can be easily manipulated by
researchers. We have therefore developed such a model, using pri-
mary tissue obtained through the Breast Cancer Now tissue bank.
Populations of myoepithelial and luminal cells were isolated from
reduction mammoplasty specimens based on their expression of
CD10 and EPCAM. These pure populations of cells were cultured
separately without losing their respective differentiated phenotype
and were susceptible to lentiviral infection, allowing genetic manip-
ulation of either cell type while in 2D culture.
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Fluorescent labelling of these cells allowed the tracking of their
behaviour once placed into a 3D environment. Once recombined,
these two cell types coalesced to form spherical and elongated duct-
like structures. These structures comprised a layer of luminal cells
surrounded by myoepithelial cells. Confocal imaging of myoepithelial
and luminal markers revealed reconstitution of a bilayer structure
absolutely reflective of normal physiology.
This novel 3D model of the human breast duct presents a powerful
tool with which to dissect myoepithelial–luminal interactions in the
early stages of breast cancer, and will help uncover markers to predict
DCIS patients who will progress towards invasive breast cancer.
A comparative study of male versus female breast
cancer identifies overexpression of eiF signalling
pathways in male breast cancer providing opportunities
for a therapeutic window
Matthew Humphries, Charlotte Suleman, Andrew Hanby
and Valerie Speirs on behalf of the Male Breast Cancer
Consortium
Leeds Institute of Cancer and Pathology, University of Leeds
Background Although rare, male breast cancer (MBC) is becoming
more common, yet remains understudied. Treatments are informed by
clinical studies conducted in women, based on assumptions that
underlying biology is the same, although evidence suggests this may
not be the case.
Methods A case-matched transcriptomic investigation of MBC and
female breast cancer was performed. Transcriptomic data was con-
firmed by qRT-PCR and biomarkers assessed immunohistochemically
on 477 MBC samples represented on tissue microarrays and related to
survival. MicroRNA (miR) expression was determined in a subset of
cases by RNA-seq.
Results Hierarchical clustering and Pathway Ingenuity Analysis
identified gender-specific gene expression patterns. Expression of
specific eIF transcripts was up-regulated in MBC, confirmed by qRT-
PCR. By immunohistochemistry, eIF4E and eIF5 were negatively
prognostic for overall survival (p = 0.012; HR = 1.77, 1.12–2.8 and
p = 0.033; HR = 1.68, 1.04–2.74, respectively). Effects on overall
survival remained independently prognostic upon multivariate anal-
ysis (eIF4E p = 0.05; HR 2.13 (1.0–4.6), eIF5 p = 0.04; HR 2.63
(1.04–6.65), respectively). Co-expression of eIF4E and -5
(p = 0.005; HR = 2.471, 1.280–4.770) also impacted on survival,
remaining so upon multivariate analysis (p = 0.002; HR 6.205,
1.99–19.30). miR analyses on a subset of MBC cases revealed
expression of 19 miRs which may regulate eIFs.
Conclusions Our findings support the notion that breast cancer is
different between genders. Overexpression of eIF4E and eIF5 sug-
gests these proteins could represent predictive biomarkers in MBC.
With mTOR inhibitors which target this pathway now in the clinic,
these biomarkers may represent new targets for therapeutic inter-
vention, although further independent validation is required.
P-glycoprotein (ABCB1) expression during breast
cancer development is regulated by HuR-dependent
loading of miR-19b at non-canonical sites
James L. Thorne1, Sebastiano Battaglia2, Samir S. Jana3, Rebecca
A. Millican-Slater4, Laura Smith5, Laura Wastall5 and Thomas A.
Hughes5
1School of Food Science and Nutrition, University of Leeds, UK;
2Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo,
USA; 3University of Calcutta, Kolkata, India; 4Leeds Teaching
Hospitals NHS Trust, Leeds, UK; 5School of Medicine, University
of Leeds, UK
Chemotherapy resistance remains a major barrier to successful breast
cancer (BC) treatment. Therapies that inhibit drug efflux pumps to
overcome resistance have failed due to off-target side effects.
Manipulating tumour-specific pathways of drug efflux pump expres-
sion could target chemoresistance, whilst simultaneously overcoming
side effects. Our aim was to examine BC-specific, post-transcriptional
regulation of P-glycoprotein (ABCB1), an efflux pump long associ-
ated with chemoresistance.
First, we determined the ABCB1 untranslated regions (UTRs)
expressed in BC and established UTRs previously implicated as regu-
latory were broadly undetectable in primary BC samples or cell lines.
Next, we screened for potential microRNA regulators by in silico pre-
diction of binding to the expressed ABCB1 30UTR. The candidate pool
was refined using a BC cohort of 302 patients by eliminating micro-
RNAs not expressed or without an inverse correlation to ABCB1
mRNA. We further screened by examining microRNA (qPCR) and
P-glycoprotein (IHC) expression across a panel of matched normal
breast, DCIS and invasive BC tissues. P-glycoprotein was significantly
up-regulated across this progression, and onemicroRNA,miR-19b,was
significantly both down-regulated and negatively correlated with
P-glycoprotein, identifying it as the single candidate regulator.
Subsequent biochemical analyses found exogenous miR-19b
overexpression reduced P-glycoprotein protein expression and
enhanced intracellular epirubicin retention and associated cell death.
Surprisingly, mutation of the predicted miR-19b seed region did not
abrogate miR-19b-dependent regulation. In fact, sequential deletion
of the UTR identified a miR-19b-responsive region devoid of a miR-
19b seed site. In silico analysis revealed a consensus sequence for the
RNA-binding factor HuR. Both activity and expression of HuR were
essential for miR-19b loading to this non-canonical site.
Although miR-19b and HuR have been reported as putative
oncogenes, their role in breast cancer appears more equivocal and
targeting either could lead to chemoresistance.
Identifying molecular drivers and early diagnostic
biomarkers in breast cancer leptomeningeal metastasis
by the interrogation of cerebrospinal fluid
Amanda Fitzpatrick, Lynda O’Leary, David Robertson, Isaac
Garcia-Murillas, Andrew Tutt, Clare Isacke
Breast Cancer Now Research Centre, Institute of Cancer Research
Introduction Breast cancer leptomeningeal metastasis (BCLM) is
particularly devastating, with a median survival of just 3–4 months.
Timely diagnosis is often challenged by low sensitivity of cere-
brospinal fluid (CSF) cytology. Further, translational progress is
hampered by the lack of in vivo BCLM models.
Methods CSF (B 10 mL) and plasma were collected from patients
with confirmed BCLM. Following protocol optimisation, cell-free
DNA (cfDNA) was extracted using Qiagen Circulating Nucleic Acid
Kit, quantified by Qubit fluorometer and fragment length assessed by
the Agilent Bioanalyzer. Primary human breast cancer cells were
injected intravenously into NSG mice. Mouse skull caps were for-
malin-fixed before dissecting out the meninges, which were stained
for human CK19 and lamin A/C, and whole-mounted for confocal
immunofluorescent imaging.
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Major findings cfDNA was extracted from CSF and plasma in 5
confirmed BCLM cases (4 luminal and 1 HER2-enriched). Median
cfDNA concentration was 9.3 ng/mL CSF (range 0.4–128.8 ng/mL).
The dominant fragment length was 149–152 bp, in keeping with
circulating tumour cfDNA size. Confocal microscopy revealed CK19
and lamin A/C-positive human tumour cells in the meninges, located
close to the dural sinuses, and individual tumour cells tracking along
vessel-like structures. Corresponding coronal brain sections revealed
tumour growth on the perimeter but not within the brain parenchyma,
in keeping with the pattern of leptomeningeal metastatic spread.
Significance of the research With the aim of developing a more
sensitive diagnostic biomarker for BCLM, CSF cfDNA will be probed
for known tumour mutations using digital PCR. To identify molecular
drivers of BCLM, CSF cfDNA will undergo exome sequencing and
comparison to plasma and primary tumour DNA. The in vivo model
will be utilised for functional evaluation of identified molecular
alterations, and for BCLM preclinical testing.
Developing in vivo models to interrogate
the mechanisms of breast cancer spontaneous brain
metastasis
Magdalena Kijewska, Marjan Iravani, Antoinette van
Weverwijk, Kuba Mieczkowski, Clare Isacke
The Institute of Cancer Research, Breast Cancer Now Research
Centre
Introduction Brain metastases develop in 15–30 % ofmetastatic breast
cancer patients, and this number is rising due to advances in image-based
detection and novel therapies that increase the survival of patients with
secondary breast cancer. The mechanisms driving site-specific brain
metastasis are mostly unknown. The major obstacle is the lack of
appropriate animal models, and very low brain metastatic burden in
existing models, which makes it difficult to study this disease.
Aims The aims of this project are to i) establish a spontaneous brain
metastasis model in immunocompetent mice, ii) identify drivers of brain
metastasis and iii) develop a method to quantify micro-metastases.
Procedures and Results We have developed a protocol where, using
the 4T1 mouse mammary carcinoma cell line, we observe a frequency
of spontaneous brain metastasis, which is representative of that seen
in clinic. We have isolated 4T1 subclones derived from the brains,
lungs and the primary tumours and performed gene expression pro-
filing. Strikingly, the lung clones showed a near-identical profile to
the tumour clones; however, the brain clones were clearly distinct
from the lung and tumour clones. We have chosen the genes of
interest to validate as potential drivers of brain metastasis and con-
firmed their differential expression in the independent brain clones
from the 4T1 model and, in an alternative MDA-MB-231 spontaneous
metastasis model, in 50 % of brain subclones. To quantify the micro-
metastasis burden, we use flow cytometry and quantification beads
that enable the absolute quantification of tumour cells in the brains.
Conclusions We will use the established in vivo models and the
tumour cell quantification, together with the molecular profiling of the
metastatic subclones, to elucidate the mechanisms enabling breast
cancer cells to spontaneously metastasis to the brain.
The role of Kindlin-1 in the initiation and progression
of breast cancer
Val Brunton, Sana Sarvi, Morwenna Muir, Helen Creedon, Adam
Byron, Hitesh Patel
University of Edinburgh
Kindlin-1 is a FERM domain-containing protein that is predominantly
localised at focal adhesion sites where it interacts with the b-subunit of
integrins and regulates their activity. It was identified as a gene whose
loss or mutation is linked to Kindler syndrome, an autosomal recessive
disease that leads to skin abnormalities including blistering and atrophy.
However, overexpression of Kindlin-1 mRNA has been reported in
colon and lung cancer and more recently Kindlin-1 mRNA expression
was associated with metastasis-free survival in both breast and lung
adenocarcinoma, although themechanisms are not fully understood. To
evaluate the role of Kindlin-1 in the initiation and progression of breast
cancer, we used the MMTV-PyMT mouse model in which Kindlin-1
was specifically excised in the mouse mammary epithelium. Kindlin-1
deletion significantly delayed tumour onset and reduced lung metas-
tasis, while primary tumour growth was unaltered. To address whether
the reduced metastatic potential of Kindlin-1-depleted tumours cells
was associated with defects in integrin activation, Kindlin-1 was
deleted in the PyMTMet-1 cell line intowhich eitherwild-typeKindlin-
1 or aKindlin-1mutant (W612A) that is unable to activate integrinswas
re-introduced. Loss of Kindlin-1 reduced early lung colonization
30 min following intravenous injection of the cells. At this time, tumour
cells have arrested in the lung vasculature and attached to the
endothelial cells prior to extravasation. Re-expression of wild-type
Kindlin-1, but not the W612A mutant, was able to rescue the lung
colonization defect, demonstrating that the ability of Kindlin-1 to reg-
ulate lung colonization is integrin dependent. Kindlin-1 deletion
reduced adhesion to both endothelial cells and the endothelial cell
adhesion molecule VCAM in an a4 integrin-dependent manner sug-
gesting that the decreased lung colonization in Kindlin-1-depleted cells
is due to an early defect in tumour cell attachment to the endothelial
cells within the lung.
Clinical research benefits from patient involvement—
the evidence
Adrienne Morgan, Maggie Wilcox, Mairead MacKenzie, Lesley
Turner, Jacqui Gath, and Pat Fairbrother
Independent Cancer Patients’ Voice
Independent Cancer Patients’ Voice is a patient advocate group led
by patients for patients. We bring the views and experience of
cancer patients, their families and carers, to the cancer research
community. We believe that clinical research benefits from patients
being partners with clinical researchers—rather than passive recip-
ients of healthcare.
‘‘The involvement of lay people in collections of tissue samples
for research has been critical in allowing professionals to feel confi-
dent about what can reasonably asked of patients. Without this input,
it is highly unlikely that our trials of presurgical treatments could have
been successful.’’
Mitch Dowsett, Royal Marsden Hospital
‘‘ICPV participation speeds up the process of turning a trial idea
into a workable design, brings a welcome new perspective to the
whole procedure and ensures the correct questions are asked.’’
Adele Francis University Hospital, Birmingham
‘‘ICPV have been invaluable to our translational research program
e.g. TRACERx, trial concept development, protocol writing and
regulatory submission. Their network and attention to detail is
unparalleled and helps us adapt to the needs of patients, rapidly
accelerating approval processes and hastening trial recruitment.’’
Charles Swanton UCLH
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‘‘ICPV has been vital in improving the POSNOC trial design,
ensuring outcomes important to patients are measured.’’
Amit Goyal Royal Derby Hospital
‘‘ICPV has influenced the design, information, consent, trial
management and processes for PERSEPHONE. Also for OPTIMA
and MAMMO-50 where ICPV organised PPI focus groups to deter-
mine the experiences and views of the trial design, information and
trial question. Engagement of patients early in the trial design has
helped with fine-tuning these important questions and has allowed the
trial team to incorporate patients’ view throughout the trial process.’’
Janet Dunn Warwick Trials Unit
‘‘ICPV have been involved in the conceptual and practical
development of the PEACE study from the outset. Their experience
and input has been invaluable.‘‘
’’Mariam Jamal-Hanjani, UCL’’
Comparing clinician and patient perspectives
in the management of hot flushes in the UK breast
cancer patients
Adrienne Morgan1, Mei-Lin Ah-See2, Myra Hunter3, Jo Armes3,
Jacqueline Filshie4
1NCRI CSG Working Party on Symptom Management; 2Mount
Vernon Cancer Centre; 3Kings College London; 4The Royal Marsden
Women who have been treated for breast cancer identify vasomotor
symptoms, such as hot flushes and night sweats (HFNS), as a serious
problem. An estimated 550 000 people live in the UK today with a diag-
nosis of breast cancer and up to 70 % experience HFNS. Oestrogen
replacement remains themost effective treatment for hotflushes.However,
this is contraindicated in women with oestrogen-dependent breast cancer.
Fewer than 50 % of women with ER+ breast cancer complete the
recommended 5 years of endocrine treatment—tamoxifen and AIs.
This lack of adherence, possibly due to unacceptable side effects,
leads to a 20 % excess breast cancer mortality.
Patient members of the NCRI Breast CSG identified that there is
very little research into the management of symptoms after breast
cancer treatment. In response, we established a Working Party on
Symptom Management. We all have an interest in the management of
HFNS, and members include patients; clinical and academic partners
representing oncology, psychology, gynaecology, and complementary
therapies; and the voluntary sector.
We gauged current clinical practice of the management of HFNS
by surveying breast cancer patients, GPs and health professionals and
we will present these data. There was a considerable mismatch
between the three groups: for example, 40 % of patients reported that
no HPs or GPs had asked them about HFNS. Despite over 90 % of
GPs and HCPs reporting that they prescribed drugs to alleviate HFNS,
only 26 % of the patients had been offered drugs and fewer than 2 %
said they helped. 31 % of the patients said that the HFNS were severe
enough for them to consider stopping endocrine therapy. If women
are to be helped to adhere to their life-saving treatment, new
approaches need to be developed to ameliorate HFNS.
What lies beneath the epigenetic signatures associated
with breast cancer and how do we find out?
Adele Murrell1, Lovorka Stojic2 and Malwina Niemczyk2
1University of Bath; 2CRUK Cambridge Institute, University
of Cambridge
Epigenetic features such as DNA methylation status, histone modi-
fications and chromatin states have been extensively profiled in the
genome. Combinatorial epigenetic marks (epigenetic signatures) are
emerging as breast cancer biomarkers and several studies are exam-
ining their diagnostic and prognostic value. However, very little is
still understood about the mechanisms that underlie aberrant epige-
netic programming in cancer cells. A specific example is long-range
epigenetic silencing (LRES) where several contiguous genes are
silenced simultaneously. We and others have shown that changes in
chromatin conformation affects DNA methylation, histone modifica-
tions and the expression of genes within looping domains. New data
from our studies in which genomic imprinting is used as a model
system show that the expression of long noncoding RNA (lncRNA)
can disrupt chromatin conformation and affect LRES through tran-
scriptional interference. Since most of the genome actually consists of
noncoding RNA, our results suggest that transcriptional interference
and chromatin topology are interdependent. In addition to having cis
functions as a result of their transcription, lncRNA can also have trans
functions away from their site of transcription. Such trans functions
are diverse but evidence is accumulating for lncRNAs having a role in
recruiting chromatin remodelling proteins to specific regions of the
genome. In a recent study in breast cancer cells, we were able to
uncouple the cis and trans functions of a lncRNA and showed that
inhibition of a lncRNA increases genes involved in the c-Met sig-
nalling pathway leading to increased cell migration and cytoskeletal
changes. This example of a lncRNA and its cis and trans functions is a
vignette of epigenetic remodelling affecting the invasiveness and
metastatic potential of breast cancer cells.
Modulation of EP300 alters paclitaxel resistance and is
accompanied by regulation of cancer stem cell markers
in breast cancer
Roman Jugov, Muhammad Asaduzzaman, Stephanie
Constantinou, Haoxiang Min, John Gallon, Meng-Lay, Charles
Coombes, Eric Lam and Ernesto Yagüe
Imperial College London
There is an urgent need to understand how cancer cells spread and to
identify markers of diagnostic and prognostic significance that can
help in the development of novel therapeutics. We have recently
described a novel pathway regulating drug resistance in breast cancer.
The three miRs in the miR-106b * 25 cluster (miR-106b, miR-93
and miR-25) target the 30-UTR of EP300, a transcriptional activator
of E-cadherin, down-regulating its expression and thus activating an
EMT program accompanied by acquisition of cancer stem cell (CSC)
properties and drug resistance.
Here, we have used a variety of breast cancer cell lines in which
EP300 expression has been stably modulated (either down-regulated
or overexpressed), as well as paclitaxel-resistant derivatives. We find
that the absence of EP300 is directly linked to paclitaxel resistance
and this is accompanied by an enrichment in breast cancer stem cell
markers (i.e. enrichment of CD44high/CD24low sub-population and
ABCG2). Importantly, cells in which EP300 has been either down-
regulated or knocked out show an up-regulation of antiapoptotic
BCL2. Interestingly, ectopic expression of EP300 in breast cancer cell
lines with mesenchymal characteristics (MDA-MB-231, CAL51)
rescues the phenotype, with depletion of the CD44high/CD24low sub-
population and resensitization to paclitaxel. Transcriptome profiling
of MCF-7 cells with EP300 down-regulation confirms that EP300 has
an important role in regulating a plethora of molecules involved in
drug resistance, motility, invasion and differentiation.
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Metaplastic breast carcinomas constitute a distinct aggressive
form of invasive breast cancer characterized by lack of E-cadherin
expression and elongated ‘‘fibroblast-like’’ cells. It is not a common
type of breast cancer, but is highly aggressive and has a poor clinical
outcome. We have analyzed by immunohistochemistry a small sam-
ple of metaplastic breast cancers and found EP300 highly down-
regulated, indicating that EP300 may play a role in the regulation of
aggressive characteristics of this form of breast cancer.
Epigenetic plasticity identifies seed breast cancer cells
driving drug resistance and metastatic progression
Sung Pil Hong, Ylenia Lombardo, Giacomo Corleone, Charles R.
Coombes, and Luca Magnani
Department of Surgery and Cancer, Imperial College London,
London, W120NN, UK
The Cancer Stem Cells (CSCs) hypothesis implies the existence of pro-
genitor breast cancer cells with de novo resistance toward antioestrogen
receptor (ER) therapies. Here we demonstrate that putative CSCs do
respond to acute endocrine therapy but are uniquely predisposed to drive
drug resistance and metastatic progression, using a noble endocrine
therapy-resistant breast cancer cell model. After reprogramming, long-
term oestrogen-deprived (LTED) cells, mimicking aromatase inhibitor
(AI) resistance, acquire cell plasticity to recapitulate the whole popula-
tion, while only CSC subpopulation of naı̈ve breast cancer cells, MCF7
and T47D, show the plasticity. Interestingly, Tamoxifen- or Fulvestrant-
resistant cells do not acquire the plasticity. Upon acute oestrogen depri-
vation, CSCs become quiescent and require additional reprogramming to
resume proliferation, while differentiated cells are efficiently cleared by
oestrogen deprivation. Potential CSC subpopulations can be identified in
patients with ERb-positive breast cancers where they are promptly
selected by short-term neoadjuvant AI therapy and further expand in
metastatic relapse following adjuvant treatment. Using ATAC-seq, we
demonstrate that CSCs are epigenetically distinct and have more acces-
sible regulatory regions than non-CSCs. The unidirectional
differentiation is achieved by loss of regulatory regions, and this chro-
matin compaction involves enhancers and promoters of Notch target
genes. These regulatory regions are maintained to be accessible in both
subpopulations of LTED cells. Using low concentration of anti-Notch
drugs, we could reduce the accessibility in the regulatory regions of
Notch target genes, and force CSC differentiation into a targetable non-
CSC subpopulation. Our data suggest that epigenetic plasticity con-
tributes to drug resistance andmight represent a novel therapeutic target.
Cadherin-5 is a biomarker for metastatic breast cancer
with optimum efficacy in oestrogen receptor-positive
breast cancers with vascular invasion
Miriam Dwek, Ruth Swann, Claire Robertson, Simon Fry
Department of Biomedical Sciences, University of Westminster
The identification of biomarkers for breast cancer prognostication and
prediction is an important aim. We have been undertaking studies to
identify proteins exhibiting alterations in glycosylation in breast
cancer. A glycoproteomic study from our laboratory identified cad-
herin-5 (CDH5) as a serum marker of metastatic breast cancer. We
validated the utility of CDH5 as a biomarker for breast cancer pro-
gression using a further series of serum samples collected from
patients enrolled in the DietCompLyf study.
A nested case–control study design was used with serum samples
from breast cancer patients who had developed a distant metastatic
recurrence within five years post-diagnosis (n = 52) and those who
had remained recurrence free (n = 60). An ELISA was used to
quantify the serum CDH5 levels and protein glycosylation was
assessed by Helix pomatia agglutinin (HPA) lectin binding. Clinico-
pathological, treatment and lifestyle factors associated with metastasis
and elevated biomarker levels were identified.
The CDH5 level (P = 0.028) and ratio of CDH5:HPA binding
(P = 0.007) were elevated in breast cancer patients with metastatic
disease. Multivariate analysis identified that the CDH5:HPA ratio and
the formation of distant metastases were driven by patients with
oestrogen receptor-positive (ER+) cancer with vascular invasion (VI+).
In conclusion, CDH5 levels and glycosylation distinguish patients
with metastatic breast cancer from those that remain metastasis free.
The test reached optimal sensitivity and specificity in ER-positive
cancers with vascular invasion.
Levels of Serpin B1 protein in white blood cells of
breast cancer patients increase in metastatic breast
cancer
Lyudmila Pavlova1, Dawn Farrar1, Jay Mani1, Gergana
Metodieva1, Metodi Metodiev1, Phil Murray2, Bruce Sizer2, Elena
Klenova1
1School of Biological Sciences of Essex, School of Biological
Sciences, Wivenhoe Park, Colchester, Essex CO
The identification of novel biomarkers to predict the aggressiveness
of breast cancer and supplement the current prognostic and treatment
tools is an important clinical need. Interaction between the host’s
immune system and tumours has been known to be reflected in
detectable changes in profiles of RNA and proteins in blood cells.
Molecules differentially expressed in these cells may therefore have
properties of cancer biomarkers. The aim of this investigation was to
identify, validate and assess the biomarker potential of proteins dif-
ferentially expressed in white blood cells (WBCs) of patients with
primary and advanced breast cancer. Using integrated approaches (2D
gel electrophoresis, high-throughput mass spectrometry and publicly
available gene expression data), protein and gene expression profiles
of WBCs were compared and a panel of 15 proteins with distinct
expression patterns in WBCs of cancer patients was selected for
further validation by RT-qPCR and Western blot assay. Our results
accumulated so far demonstrate that one of the candidates, Serpin B1
(neutrophil elastase inhibitor), present in neutrophil granulocytes, has
very promising biomarker potential. Thus, levels of Serpin B1 protein
in WBC of breast cancer patients increase as the disease advances.
Furthermore, gradual decrease of Serpin B1 levels in response to
chemotherapy and endocrine treatment is associated with favourable
prognosis. These data suggest the utility of Serpin B1 as a biomarker
of poor prognosis and treatment efficacy. The biomarker properties of
two other proteins identified in WBCs (Copine 3 and Lipocalin 2) are
currently being investigated.
Targeting PP2A to overcome resistance to HER2-
targeted therapies in breast cancer
Neil Conlon, Martina McDermott, Brigid Browne, John Crown
and Norma O’Donovan
National Institute for Cellular Biotechnology, Dublin City University,
Glasnevin, Dublin
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Aims HER2-targeted therapies, such as trastuzumab and lapatinib,
have significantly improved the outcome for patients with HER2-
positive breast cancer. However, HER2-positive metastatic breast
cancer frequently does not respond to these therapies or pro-
gresses after initial response. We have previously shown increased
protein phosphatase 2A (PP2A) activity in lapatinib-resistant
breast cancer and these cells are sensitive to PP2A inhibition.
This study examined the PP2A inhibitor LB-100, which has
recently been tested in a phase I clinical trial, in lapatinib-resis-
tant breast cancer.
Procedures Proliferation assays, using acid phosphatase assay, were
performed to assess sensitivity to HER2-targeted agents and LB-100.
Immunoblotting was performed for p-eEF2, eEF2, PPP2CA,
p-PPP2CA and PARP on lapatinib-resistant cells (SKBR3-L and
HCC1954-L) and their parental cell lines. Cell cycle analysis was
carried out using propidium iodide on a Guava EasyCyte. The effect
of PP2A inhibition on the development of lapatinib resistance was
examined by continuous exposure to lapatinib, LB-100 or combina-
tion until lapatinib-treated cell regrowth. Crystal violet staining and
quantification were used to assess cell growth.
Major findings Both lapatinib-resistant cell lines showed decreased
sensitivity to HER2-targeted agents, including neratinib and afatinib.
Both cell lines had decreased p-eEF2 and p-PPP2CA levels. These
cells were significantly more sensitive to LB-100 than their parental
cells and LB-100 had a synergistic effect in combination with lapa-
tinib in both cell lines. LB-100, as a single agent and in combination
with lapatinib, caused an increase in cells in SubG1 and increased
PARP cleavage, indicating apoptosis.
Significance of research This study shows that the therapeutic PP2A
inhibitor LB-100 may have clinical efficacy in the treatment of
refractory HER2-positive breast cancer.
Conclusions PP2A inhibition,withLB-100, causes apoptosis in lapatinib-
resistant cells and enhances response to lapatinib. Therefore, PP2A rep-
resents a novel target for lapatinib-resistant HER2-positive breast cancer.
Defining novel stromal and tumour characteristics
associated with response to neoadjuvant chemotherapy
in breast cancer
Celine Pourreyron, Shelley Waugh, Patsy Whelehan, Philip
Coates, Lee Jordan, Colin Purdie, Sarah Vinnicombe, Alastair
Thompson, Andrew Evans, Frances Fuller-Pace
University of Dundee
Introduction Neoadjuvant chemotherapy (NACT) is commonly used
in breast cancer treatment to decrease tumour and lymph node burden
and the extent of surgery. However, response is variable and prediction
poor. Our programme aims to identify peritumoural and tumour
imaging signals and stromal gene signatures which predict response to
NACT and could be used to monitor and adapt NACT.
Methods 39 patients have undergone ultrasound shear-wave elastog-
raphy and 3T MRI (including textural analysis [TA], reflecting tumour
heterogeneity, and functional tumour volume [FTV] estimations)
before, after 3 and after 6 cycles of NACT. Illumina gene expression
microarray was performed using primary stromal cells isolated from
peritumoural and tumour pre treatment core biopsies from 8 patho-
logical responders and 9 non-responders to NACT. Differentially
expressed genes (fold change C 1.2, p value\ 0.05) were identified
with MeV software. Gene expression profiles and changes in imaging
parameters are compared with percentage cellularity reduction and the
residual cancer burden (RCB) on final resection pathology.
Results Initial results show that percent reduction in FTV at
interim MRI was associated with pCR (78 % sensitivity and 89 %
specificity). Changes in TA are also associated with a greater
reduction in heterogeneity seen in good responders (pCR, RCB-1),
whereas conventional RECIST criteria performed poorly. Reduction
in peritumoural stromal stiffness showed 62 % sensitivity and 95 %
specificity for pCR. Expression profiles revealed more dysregulated
genes between the peritumoural stromal cells of responders versus
non-responders than in the corresponding tumour cells.
Conclusions Novel ultrasound and MRI imaging parameters are
superior to standard imaging methods in assessing interim response to
NACT. Gene expression discrimination between good and poor
responders to NACT is more pronounced in peritumoural stroma than
in the cancers. These pilot data provide opportunities for predictive
testing within future clinical trials.
Engineering Mesenchymal Stem Cells (MSCs) for
exosome mediated delivery of microRNAs
Killian O’Brien, S. Khan, D.P. Joyce, P. Lalor,
P. Dochery, M.J. Kerin, R.M. Dwyer
Discipline of Surgery, NUI Galway
Exosomes are small membrane-derived vesicles that are secreted by
most cells and are readily taken up by recipient cells. Exosomes
selectively package genetic material such as microRNAs, important
regulators of genes involved in breast cancer progression. Mesenchy-
mal Stem Cells (MSCs) are multipotent stromal cells known to migrate
and engraft into the tumour microenvironment where they play a key
role in intercellular communication. MSCs offer potential as vehicles
for targeted delivery of therapies. Engineering MSC-derived exosomes
secreted within the tumour microenvironment holds exciting potential.
The aim of this study was to investigate exosome-mediated cross-talk
between MSCs and breast cancer cells and to further engineer the
microRNA content of MSC-derived exosomes.
Methods MSCs were transduced with a lentivirus containing a
tumour suppressor microRNA or a control sequence, both were tag-
ged with a red fluorescent protein (RFP). Exosomes were isolated
from cell-conditioned media by differential centrifugation, micro-
filtration and ultracentrifugation. Exosomes were characterised by
transmission electron microscopy(TEM). The exosome-encapsulated
microRNA was subsequently extracted and analysed by RQ-PCR.
The impact of MSC-derived exosomes on breast cancer cell prolif-
eration was determined.
Results Exosomes were successfully isolated from the MSCs. Expected
size and morphology were confirmed by TEM. Exosome transfer onto
recipient breast cancer cells was confirmed by confocal microscopy.
Exosomal cross-talk between wild-type MSCs and breast cancer cells did
not significantly impact proliferation.MSCswere successfully engineered
to express 250-fold higher levels of the target microRNA. Exosomes from
engineered MSCs that expressed the RFP tag of the parent cell were effi-
ciently taken up by breast cancer cells, and also demonstrated a fivefold
increase in the expression of the target microRNA.
Conclusion Wild-type MSC-derived exosomes did not impact breast
cancer cell proliferation. It is also possible to engineer MSC-derived
exosomes which has exciting potential as a clinically relevant means
of therapeutic delivery.
HER2 expression levels of breast cancer cell lines grown
in 2D and 3D cell culture and sensitivity
to chemotherapeutic drugs
Tayebeh Azimi, Miriam Dwek, Anatoliy Markiv
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University of Westminster
Recently, with the advent of different methods of 3-dimensional (3D)
cell culture, scientists can now address some of the limitations of
conventional 2Dmethods. 3D cell culture systems attempt to mimic the
in vivo tumour microenvironment more accurately particularly with
respect to the gene expression profile and response to treatment. HER2
amplification occurs in approximately 20 % of invasive breast cancers
and is associated with poor prognosis and reduced overall survival.
In this study, four breast cancer cell lines which have different ER/
PR and HER2 gene expression profiles have been grown under 2D
and 3D cell culture conditions. The HER2 level has been analysed in
both conditions using mRNA and protein and by fluorescent cell
imaging. Cells were treated with the anti-HER2 drug trastuzumab and
with the chemotherapeutic agent doxorubicin and assessed using
Alamar blue as a measure of cell viability. The results show that gene
regulation and drug efficacy are affected according to the microen-
vironment in which the cancer cells are maintained.
Molecular changes in premenopausal ER+ breast
cancer after ovariectomy
Ben Haynes, O. Ginsburg, A. Gao, E. Folkerd,
M. Afentakis, Han Thi Pham, Le Hong Quang,
Ta Van To, Nguyen Van Dinh and M. Dowsett
The Ralph Lauren Centre for Breast Cancer Research, The Royal
Marsden Hospital and Institute of Cancer Research, London SW3 6JJ
Aim To characterize the molecular effects of neoadjuvant ovariec-
tomy (OvX) in ER+ breast cancers.
Background For premenopausal women, OvX is an evidence-based
cost-effective option with survival rates comparable to first-genera-
tion chemotherapy and is standard treatment in many countries. There
are virtually no data describing the biological effects of OvX in
premenopausal breast cancer.
Patients and Methods A non-randomized phase II trial of neoadju-
vant OvX was conducted in 56 premenopausal women with
ER+ breast cancer in Vietnam. Serum and tumour samples were taken
at diagnosis, oophorectomy (t = 2 weeks) and mastectomy
(t = 4 weeks). Serum hormone concentrations were measured by
RIA. Ki67, ER, PgR and HER2 were measured by IHC. RNA was
subject to whole-genome expression profiling (32 pairs).
Results Estradiol concentrations decreased from 421 ± 305 to
24.1 ± 24.5 pmol/l (mean ± SD) 24 h after OvX and to
8.8 ± 7.3 pmol/l by mastectomy. Ki67 decreased in 33/36 (91.7 %) of
tumours: the changes did not differ according toHER2 status. AfterOvX
the expression of 756 genes changed significantly (p\ 0.005) with fold
change (FC)[ 1.25. TFF1 was the most highly down-regulated gene
(FC0.20; p\ 1e-07); other oestrogen-regulated (e.g.GREB1, PDZK1,
PGR) and proliferation-associated genes (e.g. TOP2A, CDC20) also
showed large decreases in expression (FC 0.41–0.69: p\ 1e-07).
Progesterone-regulated genes, e.g. FKBP5, ESRRA, were also down-
regulated. Changes in gene expression after OvX strongly correlated
with those after aromatase inhibitor (AI) treatment in postmenopausal
women (r = 0.87, p\ 1e-04) [1]. AfterOvX,more than twice asmany
genes showed a FC[ 1.25 (721 vs. 331) and the mean FC was signifi-
cantly higher (p\ 1e-04) compared to AI.
Conclusion Molecular changes in ER+ breast cancer after OvX in pre-
menopausalwomen are similar to those afterAI in postmenopausal patients.
However, OvX affects more genes and has a greater impact on them.
[1] Clinical Cancer Research 2013;19:2775
Use of CRISPR–Cas9-mediated knockin mutagenesis
of ESR1 mutations in metastatic breast cancer allow
functional analysis and evaluation of treatment options
Joel Fulton, Alison Harrod, Van Nguyen, Manikandan
Periyasamy, Laura Ramos Garcia, Chun-Fui Lai, Alex de
Giorgio, Gergana Metodieva
Imperial College London
As themajor driver of breast cancer (BC) development and progression,
ERa is the predominant target for adjuvant therapies. Inhibition of ERa
activity with anti-estrogens or inhibition of estrogen biosynthesis (aro-
matase inhibitors, AI) reduces relapse and improves patient survival.
However, many patients with ERa-positive BC relapse on these thera-
pies, resistant tumours mostly remaining ERa positive. Efforts to
identify changes in ERa that functionally act in resistance show that
mutations in the ERa gene are exceptionally rare in primary BC. By
contrast, recent discoveries show that ERa is frequently mutated in
Endocrine-resistant metastatic breast cancer. These reports provide
strong evidence for treatment-selective pressure leading to acquisitionof
ERa mutations. To determine the function of these mutations, we used
the CRISPR–Cas9 system to generate the common (L536R, Y537S,
Y537 N, Y537C, D538G) mutations in the genetically encoded ERa
gene inMCF7 cells. Evaluation of ERa recruitment to DNA (ChIP-seq)
and expression profiling (RNA-seq) demonstrate that the mutations
result in estrogen-independent expression of many ERa target genes,
accompanied by estrogen-independent growth and partial resistance to
anti-estrogens. We will further also present evidence that inhibitors of
key signalling pathways regulating ERa activity provide a means of
restoring anti-estrogen responsiveness. Therefore, these mutant breast
cancer cell lines provide an important resource for determining
approaches for the treatment of breast cancer featuring ERa mutations.
WSB-1 regulates the metastatic potential of hormone
receptor-negative breast cancer
Isabel Pires, Flore-Anne Poujade, Lisa Eigleman, Aaren
Mannion, Ellie Beeby, Sage Pickwell, Andrew Theodosi,
Christopher Cawthorne
University of Hull
Metastatic burden is responsible for the majority of cancer-associated
deaths. Therefore, it is of utmost importance to clarify the mechanisms
underlying tumour cell spread. This will allow the development of
better cancer prognostic tools and therapeutic approaches. The tumour
microenvironment is a major driver of metastatic disease. Particularly,
hypoxia is associated with therapy resistance and increased tumouri-
genic and metastatic potential. Although some of the factors important
for regulation of hypoxia-associated metastasis have been identified,
many aspects of this phenomenon still remain unclear.
The aim of this study was to investigate the role of the poorly
characterised WSB-1 (WD40-repeat and SOCS Box containing-1) E3
ligase in breast cancer biology, particularly in the context of tumour
microenvironment conditions, such as hypoxia.
We have identified WSB-1 as a hypoxia-inducible factor in a wide
variety of breast cancer cell lines. In silico analyses indicated that high
WSB-1 expression was associated with decreased distant metastasis-
free survival and relapse-free survival in a cohort of ER- and PR-neg-
ative breast cancer patients. Knockdown of WSB-1 expression led to
decreased in vitro cellular migration and invasion, aswell as angiogenic
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potential, but only for ER- and PR-negative cell line models. This was
associated to alteredMMP expression and activity, as well as decreased
expression and secretion of VEGF. Importantly, knockdown ofWSB-1
was also associated with decreased metastatic burden for in vivo
experimental models of metastasis.
The present study indicates that the hypoxia-inducible factor WSB-
1 has a role in regulating metastatic spread in breast cancer, specifically
in the context of hormone receptor biology. Further clarification of the
signalling pathways involved in mediatingWSB-1 function will clarify
novel aspects of aggressive metastatic disease in breast cancer.
Pro-inflammatory cytokines promote adhesion of breast
tumour cells to brain endothelium
Ester Pascual-Baixauli, C. Cerutti1, E. Garattini2, I.A.Romero1,
F. Crea1
Department of Life Health and Chemical Sciences, the Open
University, Milton Keynes MK7 6AA UK;
1The Open University, Milton Keynes;
2Mario Negri Institute, Milan, Italy
Metastatic spreading is the main cause of death in breast cancer
patients. Brain metastases are resistant to most available treatments
and associated with particularly poor prognosis. The development of
metastases is a multi-step process. While most of these steps have
been extensively studied, the adhesion of cancer cells to the vascular
endothelium is not well characterised. Pro-inflammatory cytokines
(IFNc/TNFa) promote breast cancer dissemination to the brain.
However, the mechanisms and clinical significance of this phe-
nomenon have not been elucidated.
We developed a micro-fluidic system that enables us to measure
the adhesion of breast cancer cells to brain endothelial cells (hCMEC/
D3), under shear stress conditions. We exposed hCMEC/D3 cells to
IFNc and TNFa (1 ng/ml) or vehicle and measured the relative
adhesion of breast cancer cells. We found that cytokines significantly
enhanced the adhesion of MDA-MB-157 cancer cells to hCMEC/D3
cells ([50-fold change vs. control, P\ 0.05). This result has been
replicated in HCC1954 and HCC114vvc3 cells. Our proteomics
analysis revealed that IFNc and TNFa significantly up-regulated the
expression of VCAM1 and LGALS9 cell adhesion molecules in
hCMEC/D3 cells (3.219 ± 0.372, 2.338 ± 0.595 fold change vs.
control, respectively).
In order to identify the molecular mechanisms of cancer/en-
dothelium interaction, we employed a pathway analysis software and
identified putative ligands of VCAM1 and LGALS9, then examined
the expression of these ligands in a database that includes 1609 breast
cancer clinical samples. We found that the ITGA9/ITGB1 dimer
(VCAM1 ligand) and the P4HB protein (LGALS9 ligand), are highly
expressed in breast cancer cells. More importantly, ITGA9/ITGB1
and P4HB up-regulation predicted shorter metastasis-free survival in
patients (log-rank p values = 0.0011 and 0.0066; hazard ratios: 1.43
and 1.34, respectively).
These results indicate that pro-inflammatory cytokines could
promote breast cancer metastatic tropism via up-regulation of specific
cell adhesion proteins.
Impact of tyrosine kinase expression levels in human
breast cancer cells on their response to treatment
with combinations of small-molecule tyrosine kinase
inhibitors
Aryan Stanley, Helmout Modjtajhedi
Kingston University
Despite recent advances in diagnosis and treatment, breast cancer
remains one of the leading causes of mortality worldwide, highlighting
the need for development of more effective therapeutic interventions
and the identification of more reliable predictive markers of response to
therapy. Here, we investigated the sensitivity of a panel of breast cancer
cell lines to treatment with various tyrosine kinase inhibitors (TKIs),
including reversible and irreversible ErbB-family inhibitors, and inhi-
bitors of Src/Abl (dasatinib) and c-Met/ALK (crizotinib), as single
agents and in combination, and whether there was any association
between expression level of target antigens and response to treatment.
The effects of these agents on cell downstream signalling and tumour
migration were also investigated using Western blot and cell migration
assay. Of the ErbB-family inhibitors, the irreversible pan-ErbB inhi-
bitors were generally more effective at inhibiting cell growth than their
reversible counterparts. We found the combinations of ErbB-family
inhibitors with dasatinib were synergistic in the HER-2- and EGFR-
overexpressing BT474 and MDA-MB-468 cells, respectively, both of
which also had high levels of pSrc. Interestingly, the same combinations
were antagonistic in SKBr3 cells which also hadHER-2 overexpression
but lower levels of pSrc. When the ErbB-family inhibitors were com-
binedwith crizotinib, their effectsweremainly synergistic inMCF7 and
MDA-MB-468, but mainly antagonistic in the HER-2-overexpressing
SKBr3 andBT474 cells. Of all the TKIs examined, we found canertinib,
dastinib, sapitinib and afatinib to be the most effective for reducing the
migration of highly migratory MDA-MB-231 cells. Finally, with the
exception of HER-2 and canertinib, we did not find a significant asso-
ciation between the expression level of other target antigens and
response to these treatments. Our results suggest that while these
inhibitors may have improved efficacy in combination, further inves-
tigations are warranted for the prediction of response to these
therapeutic interventions in breast cancer.
Targeting breast cancer stem cells through their
P-Rex1/Rac1 signalling
Ahmet Ucar, David Novo, Keith Brennan, Rob Clarke, Charles
Streuli
University of Manchester
Breast cancer is the second most common cause of death from cancer
in women in the UK. Although conventional and targeted therapies
can prolong disease-free survival of patients, acquired drug resistance
and tumour relapse are frequently observed in clinics. At the core of
this clinical problem are breast cancer stem cells (Br-CSCs), a small
fraction of tumour cells with stemness features and the capacity to re-
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initiate tumour formation. Br-CSCs are likely to be responsible for
primary tumour formation, metastasis, acquired drug resistance and
tumour recurrence. Using pharmacological inhibitors, we have
determined that the activity of the small GTPase Rac1 is essential for
the self-renewal and maintenance of Br-CSCs. Additionally, we have
used the CRISPR-Double Nickase approach of genome engineering to
address the roles of Rac1 signalling pathway in Br-CSCs. We have
determined that loss of function of P-Rex1, an upstream regulator of
Rac1 that is highly expressed in luminal breast tumours, results in
premature differentiation and thereby depletion of Br-CSCs. We have
also shown that the tumour-specific splice variant of Rac1, Rac1b,
regulates Br-CSC plasticity. Moreover, genetic deletion of Rac1b
leads to a transition of Br-CSCs into a chemotherapy-sensitive state.
Our study reveals that P-Rex1 and Rac1b are two attractive molecular
targets for the elimination of Br-CSCs.
A lump and a bump: My experience of the breast
cancer journey while pregnant and with a young baby
Cassandra Tait, Patient Advocate
When diagnosed with breast cancer while 13 weeks pregnant, the lack
of experience of pregnancy in cancer practitioners (and of cancer in
antenatal practitioners), their reluctance to commit to treatment plans
and the consistent changes of plans for baby and myself were
apparent. My journey through treatment became one of isolation, fear
and confusion as treatment plans changed and birth plans were not
considered. The rarity of breast cancer during pregnancy became clear
when my story began with ‘‘it’s just a blocked milk duct’’, included a
nurse telling me he felt uncomfortable giving me chemotherapy while
pregnant, a 2-week stay in intensive care for my newborn baby, night-
feeds following chemotherapy cycles and is now coming to a hopeful
conclusion with an ongoing battle between effective and meaningful
parenting and debilitating fatigue.
My experiences highlighted a need for patients to be put in touch
with others experiencing the same or similar to avoid isolation. In
addition, there is a gap in the psychological services available to
women in the specific position of fearing for the life of their unborn
child, as well as their own. Moreover, the complexity of the side
effects of treatment appears heightened when there is a need to care
for a very young baby (and 4 years old).
Endothelial HIF-a modulate cancer metastatic potential
by affecting vascular permeability and pro-metastatic
macrophage infiltration
Cristina Branco, Colin Evans, Renato Colaco, Helene Rundqvist,
Randall Johnson
University of Cambridge
Endothelial cells play a central role in the process of metastases, as
the endothelium is the first physical barrier separating the primary
tumor from the rest of the organism. To prevent metastatic events is a
major concern in breast cancer treatments, as this is the phenomenon
ultimately associated with mortality and morbidity. We have
previously shown that deletion of endothelial Hypoxia-Inducible
Factors (HIFs) strikingly affects metastatic success in an isoform-
specific manner (Branco-Price et al., Cancer Cell, 2012). In this work,
we show that acute hypoxia predisposes lungs for metastatic colo-
nization. This correlates with increased HIF-1a, increased endothelial
permeability, and increased levels of MCP1, which we believe is
secreted, to a significant extent, by endothelial cells. Chronic hypoxia,
however, does not seem to predispose lungs for tumor growth in any
manner different from normoxic preconditioning, in spite of increased
macrophage infiltration into lungs. Our observation suggests that a
combination of increased permeability and specific prometastatic
macrophage infiltration enhances metastatic potential, in a process
that is mediated by endothelial HIF-1a, and we can reverse this
phenomenon in mice lacking lung endothelial HIF-1a. In chronic
conditions, where HIF-2a is preferentially activated and HIF-1a is less
prevalent, mice develop secondary tumors to an identical extent to
those kept in normoxia. We are further exploring the consequences of
vascular occlusion and localized hypoxic insult, as seen during cir-
culating tumor cell arrest in small capillaries, having observed that an
acute and localized hypoxic insult following inflammation has a
potentiating effect in metastatic proliferation, whereas a microoc-
clusion that occurs at the same time or earlier than tumor cell
injection has no effect. The mechanisms underlying this phenomenon
appear to depend on both endothelial and inflammatory responses: a
fine balance in endothelial activation, inflammatory components, and
dynamic stabilization of HIF isoforms that significantly affect meta-
static predisposition.
ICEC0942, an orally bioavailable selective inhibitor
of CDK7 for breast cancer
Simak Ali1, Hetal Patel1, Manikandan Periyasamy1, Alexander
Bondke2, Brian W. Slafer2, Silvia Ottaviani1, Alison Harrod1,
Laki Buluwela1, Matthew J. Fuchter2, Anthony, G. M. Barrett2,
R. Charles Coombes1
1Department of Surgery & Cancer; 2Department of Chemistry,
Imperial College London, UK
Estrogen receptor-a (ER) is the transcriptional driver in the majority
of breast cancers. ER activity is targeted with inhibitors of estrogen
biosynthesis or with anti-estrogens, such as Tamoxifen. While these
drugs have been extremely successful, many patients relapse, with
few treatment options being available following emergence of resis-
tance. Recent reports show that many cancer types are highly
sensitive to transcription inhibition, suggesting that targeting the
transcriptional machinery provides new approaches to cancer treat-
ment. Cyclin-dependent kinase (CDK)7, which is required for RNA
polymerase II-mediated transcription, also regulates the activities of
several transcription factors, including ER. We have identified a new
selective inhibitor of CDK7, ICEC0942. In vitro studies show that a
wide range of cancer types are sensitive to CDK7 inhibition. In
xenografts of both breast and colorectal cancers, the drug has sub-
stantial antitumour effect. Additionally, combination therapy with
tamoxifen showed complete inhibition of ER-positive tumor xeno-
grafts. Our findings reveal that CDK7 inhibition provides a new
approach for treatment of ER-positive breast cancer and identify
ICEC0942 as a prototype drug with potential utility as a single agent
or in combination with hormone therapies.
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Targeting folate receptor alpha for breast cancer
treatment
Anthony Cheung, James Opzoomer, Kristina Ilieva, Rebecca
Marlow, Erika Francesch Domenech, Matthew Fittall, Patrycja
Gazinska, Natalie Woodman, Gyula Petranyi, Nirmesh Patel,
Hasan Mirza, Sarah Pinder, Cheryl Gillett, Anita Grigoriadis,
Frank Nestle, James Spicer, Andrew Tutt and Sophia
Karagiannis
King’s College London
Promising targeted treatments and immunotherapy strategies in
oncology and advancements in our understanding of molecular
pathways that underpin cancer development have reignited interest in
the tumour-associated antigen Folate Receptor alpha (FRa). FRa is a
glycosylphosphatidylinositol (GPI)-anchored membrane protein. Its
overexpression in solid tumours such as ovarian, breast and lung
cancers and low and restricted distribution in normal tissues, along-
side emerging insights into tumour-promoting functions, together
render FRa an attractive therapeutic target.
We demonstrated expression of FRa in basal subtypes of breast
cancer in the King’s College London and METABRIC genomic data-
sets. In combination with RNA interference experiments, we showed
that the inhibition of FRa reduced cellular proliferation, colony for-
mation and ERK activation in FRa-expressing breast cancer cell lines.
A monoclonal antibody targeting FRa, MOv18 IgE, is already in a
phase 1 clinical trial in ovarian cancer, and is being explored in our
laboratory as a novel first-in-class IgE immunotherapy for the treat-
ment of breast cancers. Using a multi-colour flow cytometry-based
in vitro tumour cell killing assay, we demonstrated the ability of
MOv18 to induce antibody-dependent cell-mediated cytotoxicity
(ADCC) against FRa-expressing breast cancer cell lines by human
monocytes and healthy volunteer peripheral blood mononuclear cells.
In addition, we evaluated expression of FRa in immuno-humanized
xenograft models using immunohistochemistry and we found poten-
tial models for further in vivo efficacy studies.
In summary, our findings demonstrate that the tumour antigen FRa
is expressed in basal breast cancers and its expression may support
cancer cell growth. Functional studies with an anti-FRa monoclonal
antibody warrant further characterisation of this antigen as a potential
new therapy target in subsets of breast cancer, especially triple-neg-
ative breast cancers, for which effector cell infiltration is already
known to be favourably prognostic.
Breast Cancer Now Cell Culture Programme:
a bespoke resource for the research community
J. Louise Jones, Jenny Gomm, Linda Haywood, Adrienne
Morgan, Iain Goulding, Mike Allen, Claude Chelala, Emanuela
Gadelata
Barts Cancer Institute, Queen Mary University of London
The Breast Cancer Now Cell Culture Programme is part of the Breast
Cancer Now Tissue Bank and is a unique initiative aimed at providing
primary cells and ‘live’ tissues to the research community. The Pro-
gramme utilises a broad range of tissues including normal breast
tissue, prophylactic mastectomy tissue from high-risk individuals,
including BRCA1 and BRCA2 mutation carriers, breast cancer tissue
and matched material taken adjacent to (\2 cm) and distant from
([5 cm) the cancer, as well as tumour cells derived from lymph node
metastases. Tissue is digested and different cell populations isolated,
including from non-tumour tissues luminal epithelial, myoepithelial
and fibroblast populations. From tumour-derived samples, fibroblasts
and tumour cell-enriched populations are generated. In some cases,
samples are digested only to organoid stage and can be provided as
such, or single-cell unsorted preparations can be provided for sub-
sequent sorting and characterization. Sample sets can be provided,
including matched tumour-associated fibroblasts and surrounding
non-tumour fibroblasts, matched tumour cell-enriched preparations
and fibroblasts, and matched non-tumour-associated cells. In addition
to cell preparations, explant culture material also is available: pieces
of tumour or non-tumour material, 2 9 2 9 2 mm, that can be cul-
tured for varying periods (currently data from samples cultured
between 5 and 25 days) under different conditions. All samples have
linked comprehensive clinicopathological information and can also be
linked to matched tissue samples from the Tissue Bank.
The Breast Cancer Now Cell Culture Programme also operates an
R&D programme to enhance the utility of the samples provided. This
includes culture of cells on different matrices and scaffolds, extensive
biomarker characterization, and an immortalization schedule, to
increase the availability and longevity of the samples. Selected samples
are currently undergoing Whole-Genome Sequencing and these data
will become available through the BCNTN Bioinformatics Portal.
Breast cancer and return to work: a pilot
Julie Denning, N. Hunter
Working Towards Wellbeing
Around 100,000 people of working age are diagnosed with cancer
yearly. However, as treatments for cancer improve, increasing num-
bers of people become ‘cancer survivors’, wanting to return to normal
functioning including work; however, they are 1:4 more likely to be
unemployed than matched controls. Work has been shown to be good
for health (Burton, Waddell and Kendal, 2008) and improves function
and general wellbeing post diagnosis.
Research suggests that people surviving cancer want to return-to-
work (Amir et al., 2008, Macmillan, 2008). However, most rehabil-
itation services do not address return to work or the associated
physical, emotional and practical issues affecting cancer survivors
such as fatigue, pain, financial problems and reduced self-efficacy.
Providing support through multilevel case management is predicted
to help people on their return-to-work journey as research byMacmillan
has shown that such Vocational Rehabilitation (VR) services are ben-
eficial. This research aims to build on their findings by providing a
stepped care model within a population of income protection claimants
to ascertain whether a VR service can have a positive impact on return-
to-work outcomes and physical and psychological factors.
A longitudinal pilot study of 32 people was carried out to explore
improvements in mood, fatigue, quality of life, self-efficacy, readi-
ness to return to work and satisfaction.
58 % of the group returned to work. There was a 34 %
improvement in the Chalder Fatigue Scale, 48 % improvement in the
GAD7, 52 % improvement in the PHQ9, 11 % improvement in Self-
efficacy Scale, and a 32 % improvement quality of life.
The findings from this pilot study are positive and suggest that
there is a need for VR services for people who have survived cancer
to improve their quality of life including return-to-work plans.
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Cytidine deamination activity of APOBEC3B regulates
estrogen receptor function in breast cancer
Manikandan Periyasamy, Van T. M. Nguyen, Hetal Patel, Chun-
Fui Lai, Ekaterina Nevedomskaya, Alison Harrod, Laki Buluwela
and Simak Ali
Imperial College London
We have discovered that APOBEC3B (A3B), recently linked to the
mutational landscape in breast and other cancer types, is required for
breast cancer cell growth. Using ChIP-seq and RNA-seq profiling, we
have shown that A3B is recruited to the majority of ER-binding
regions in ER? breast cancer cells, to regulate ER target gene
expression. Mechanistic studies established that A3B regulates gene
expression causing C-to-U deamination at ER-binding regions. We
show that these C-to-U changes lead to the generation of DNA strand
breaks through activation of base excision repair (BER) and to repair
by non-homologous end-joining (NHEJ) pathways. These studies
demonstrate that the transient cytidine deamination by A3B aids
chromatin modification and remodeling at the regulatory regions of
ER target genes, which promotes their expression. Furthermore,
extending the genomic profiling to other breast cancer cell lines
shows that A3B is an important transcriptional regulator in ER-pos-
itive and in ER-negative breast cancer. Furthermore, these findings
also provide insights into potential mechanisms by which transcrip-
tion factor-mediated recruitment of A3B to DNA may facilitate
cancer mutations by A3B.
Investigating the role of RUNX2 in the breast cancer
microenvironment
Nicholas Rooney1, Laura McDonald1, Joanna Morris2, Ewan
Cameron2, Joanne Edwards2, Karen Blyth1
1CRUK Beatson Institute, Bearsden, Glasgow, G61 1BD; 2University
of Glasgow, Garscube Estate, Bearsden, Glasgow, G61 1QH
The stromal microenvironment associated with epithelial tumours is
known to have a profound influence on the transformation, progres-
sion and dissemination of cancers. Currently, little is known about the
transcription factors within stromal cells that are responsible for
regulating these processes. RUNX2 is a highly conserved transcrip-
tion factor that is absolutely required for normal mammalian bone
development. RUNX2 has also been shown to be expressed in the
normal mammary gland and has been implicated in breast cancers,
where it is highly expressed in metastatic breast cancer cell lines. To
date, very little is known about the role of RUNX2 within the
mammary stromal microenvironment and what effect this has in the
context of breast cancer. Here we confirm in an analysis of a human
tissue microarray from 417 patients with primary breast cancer that
RUNX2 is more highly expressed in the stroma of breast cancers
compared to the epithelium and that this high expression correlates
with poor prognosis in ER-negative tumours. In addition, we show
that RUNX2 is clearly expressed in the stroma of tumours derived
from the MMTV-PyMT (mouse mammary tumour virus-polyoma
middle T antigen) GEM model of breast cancer. Immuno-
histochemical analysis shows that RUNX2 expression correlates with
fibroblast markers rather than immune cell markers. We then used
FSP-Cre (fibroblast-specific protein-1) to specifically delete one copy
of Runx2 in the PyMT model (FSP-Cre?; PyMT?; Runx2fl/?). This
revealed that heterozygous deletion of Runx2 in fibroblasts increases
the average lifespan of the mice and improved overall survival. FSP-
Cre ? ; PyMT ? ;Runx2 fl/? mice also had increased tumour-free
survival, and a delay in tumour progression to clinical endpoint
compared to wild-type FSP-Cre?; PyMT?; Runx2?/? mice. Toge-
ther, this indicates that Runx2 is highly present in the stroma of breast
cancers and that reduction in its stromal expression can delay breast
cancer progression.
Circulating nucleic acids for monitoring metastatic
breast cancer
Allison Hills
Currently, there is a limited clinical ability to monitor breast cancer
patients for signs of drug resistance at the molecular level. Devel-
opment of minimally invasive blood-based assays, with a focus on
Circulating Tumour Cells (CTCs) and circulating cell-free DNA
(cfDNA), offers opportunities for real-time monitoring and treatment
stratification that could significantly impact on patient outcome.
CfDNA is potentially easier to obtain than CTCs and so it is important
to determine which, if either, the more suitable candidate for clinical
use is. The purpose of this study was to directly compare the muta-
tional profiles of multiple single CTCs and cfDNA isolated from the
same blood samples taken from patients with metastatic breast cancer
(MBC). MBC patient blood samples were enriched for EpCAM-
positive CTCs by CellSearchTM and a count obtained for each sample.
In 5 patients with C100 CTCs per 7.5 ml blood, multiple single CTCs
were isolated by DEPArrayTM. Next-generation sequencing (NGS) of
*2200 mutations in 50 known cancer genes was performed on iso-
lated single CTCs, cfDNA from the same blood sample, and matched
primary tumour tissue. NGS analysis of 40 individual CTCs from 5
MBC patients revealed mutational heterogeneity in PIK3CA, TP53,
ESR1, and KRAS genes between individual CTCs in 4/5 patients. In
all 4 patients, matched cfDNA profiles provided an accurate reflection
of mutations observed in individual CTCs; however, more mutations
were detected in cfDNA than in matched CTCs. One patient had no
mutations in cfDNA or CTCs. ESR1 and KRAS gene mutations were
absent from primary tumour tissue and therefore likely reflect either a
minor sub-clonal mutation or were acquired with disease progression.
Our results demonstrate that cfDNA reflects persisting EpCAM-pos-
itive CTCs in patients with high CTC counts and may enable
monitoring of the metastatic burden for clinical decision making.
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